

# Improving Outcomes with Personalized, Patient-Centered Care

 **NorthShore**  
University Health System

**Kellogg Cancer Center**

**2022 ANNUAL REPORT**

NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center (Kellogg) brings together the highest level of clinical care, patient and family support, medical education and vital translational research. Our patients benefit from individualized treatment plans based on the most sophisticated genomic and tumor analysis available.

Our integrated team of expert physicians, nurses and other specially trained clinicians work collaboratively to ensure that patients receive the most compassionate, evidence-based care. A broad array of clinical trials provide access to the latest innovative therapies, and an ongoing investment in technology keeps Kellogg at the forefront of advances in early detection and advanced treatment.

As the NorthShore system grows, we look forward to collaboration and integration of cancer care at Swedish, Northwest Community and Edward-Elmhurst Hospitals and expanded community partnerships to benefit our patients.

The Kellogg Cancer Genomic Initiative (KCGI) continues to grow and provide more information about genetic markers and gene mutations that can profoundly impact treatment plans and improve outcomes for our patients. The KCGI truly differentiates NorthShore from other area providers, and we are proud to be setting new standards of care for cancer patients.

Our academic affiliation with the University of Chicago Pritzker School of Medicine not only helps train the next generation of physician leaders, but also allows our patients to continue to benefit from our shared clinical and research initiatives and collective expertise.

NorthShore is certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as a premier medical provider for practicing the highest standards of quality cancer care. The Commission on Cancer has continuously accredited NorthShore as an Academic Comprehensive Cancer Program since 1981.

From its earliest days, the Kellogg Cancer Center has been the recipient of generous charitable support. Philanthropy is central to our success as donors have elevated every aspect of the program and allowed us to do more for patients. Philanthropy backs groundbreaking research initiatives and clinical trials and allows us to move quickly, bringing the latest findings from the lab to the bedside, harnessing the power of novel treatments for patients without delay, and providing a deep array of supportive services to our patients to further personalize our care.

We remain humbled, particularly by grateful patients and family members who support the Kellogg Cancer Center with generous donations. We are so very thankful to each and every donor who makes our continued efforts to provide life-changing cancer care possible.

We are pleased to present this report, which highlights some of the important progress and developments of the past year, and we thank you for your interest in our mission to provide transformative cancer care.



Dr. Bruce Brockstein



Dr. David J. Winchester

**Bruce Brockstein, MD**  
 Medical Director,  
 NorthShore Kellogg Cancer Center  
 Division Head, Hematology Oncology  
 Kellogg-Scanlon Chair of Oncology

**David J. Winchester, MD**  
 Chairman, NorthShore Cancer Committee  
 Associate Director for Surgical Specialties  
 NorthShore Kellogg Cancer Center  
 Board of Directors  
 David P. Winchester, MD, Chair of Surgical Oncology



# Immunotherapy—Driving Major Advances in Treatment


Just a few years ago, only 20% of cancers were treatable by immunotherapy. Today, however, immunotherapy plays a role in nearly 40% of cancer treatments. NorthShore remains ahead of the curve in offering these pioneering therapies that harness the body's own immune system to identify and eradicate cancer cells.

Beginning with clinical trials and compassionate use of commercially available drugs, our clinicians have worked together to share expertise and minimize side effects while imparting long-term benefits for a growing number of patients.

New programs, like our CAR T-cell therapy, will help pave the way for other treatments including the first-ever treatment for ocular melanoma—an immunotherapy drug that has a similar side effect profile to CAR T-cell therapy. NorthShore is also advancing the use of oncolytic viral injectable immunotherapy for subcutaneous and other melanomas.

Thoracic surgeon Seth Krantz, MD, and oncologist Tom Hensing, MD, have been recognized for their work devoted to predictive modeling and related benefits of immunotherapy for lung cancer patients. Dr. Hensing leads a team partnering with West Virginia University and Case Western Reserve University in a groundbreaking study. Kellogg Cancer Center continues to lead and participate in numerous immunotherapy clinical trials.

## Immunotherapy Total Number of Patients and Doses



## CAR T-Cell Program for Lymphoma Patients



Lymphoma specialists Dr. David Grinblatt (from left), Advanced Practice Nurse Mila Ter-Saakyants, Dr. Amy Wang and Dr. Lynne Kaminer are part of the team offering promising new immunotherapy treatment to patients with relapsed lymphoma.

Led by hematologist David Grinblatt, MD, our recently certified program offering CAR T-cell treatment for lymphoma patients is one of the first non-university-based programs in the state. The promising FDA-approved therapy is the best new option for patients with relapsed or refractory lymphoma. CAR T-cell therapy involves chimeric antigen receptor (CAR) genetically modified T cells that are designed to recognize specific antigens on tumor cells, which then activate and proliferate to destroy malignant cells. The patient's own immune cells are collected by a process similar to dialysis, engineered to fight the lymphoma cells and then given back to the patient. "This is an important move forward for patients whose disease was not responsive to other treatments," said Dr. Grinblatt.



# Sophisticated Cancer Screenings, Enhanced Personalized Medicine

NorthShore is bringing sophisticated laboratory cancer screening innovations to our primary care patients through new research studies not available at any other system in the state. Using an investigational blood-based cell-free DNA platform in conjunction with current, evidence-based

cancer screening modalities, these research studies aim to improve the ability to detect cancers earlier and improve outcomes compared to standard cancer screening alone. All cells have DNA, a blueprint that tells the cell how to build itself.

Cancer is the result of mistakes in DNA, telling the cell to grow and act in an uncontrolled way. Most normal cells turn over, meaning there is some amount of both cell division and cell death. When a cell dies, it releases DNA outside the cell and thus the DNA can be detected in blood.

Some drugs exist that target specific DNA “mistakes,” and advanced testing helps identify the biomarker-specific therapy.

NorthShore’s expert Pathology and Laboratory Medicine Department performs the advanced tests in-house, allowing for faster turnaround times and better communication between the lab team and clinicians on complex cases. The laboratory team is exploring development of new cell-free DNA testing for Kellogg Cancer Center patients to continue to enhance personalized therapy.



Dr. Mir Alikhan (left) and Dr. Megan Parilla are key members of the Molecular Diagnostics team helping to bring major advances in diagnostic testing and more to Kellogg Cancer Center patients.

## Kellogg Cancer Genomic Initiative


Next-generation tumor sequencing to characterize the tumor mutations of patients with advanced or metastatic cancer to help determine the best course of therapy is progressing in the Kellogg Cancer Genomic Initiative (KCGI). Nurse Practitioners Gayathri Moorthy, PhD, and Annette Sereika, APN, work with patients joining the study, explaining the study and how their participation can potentially help with their treatment. When genomic abnormalities are found, together with the molecular pathology team, they then conduct literature reviews to see which drugs may have utility for a specific patient’s mutation.

As part of the KCGI trial, patients receive pharmacogenomics testing to learn about their body’s ability to react to various medications.

As a nurse who also holds a PhD in molecular biology, Dr. Moorthy is a perfect fit for the multidisciplinary KCGI team working to push the boundaries and do more with genomic information. “As an organization we want to do everything we can. We want to really stretch for each patient in our care,” she said, “and this kind of personalized medicine helps us do that.”

“KCGI really leverages the strengths of NorthShore’s molecular pathology and bioinformatics teams,” said Sereika, “and the success of the study is the result of the tremendous teamwork of so many different departments.”

To date, 164 patients have been enrolled in KCGI.



# Genomic Testing Offers Hope, Healing

**C**hantay Gresham has had more than her share of struggles, preparing to die at just 46 years old. But thanks to her care from oncologist Bruce Brockstein, MD, and her participation in the Kellogg Cancer Genomic Initiative (KCGI), she has hope and a new lease on life.

When Gresham found her way to the Kellogg Cancer Center team, she was incredibly sick with a large and very rare sarcoma tumor that had grown in her abdomen, interfering with her liver and kidney function. She first started feeling ill in May 2021. Unable to keep any food down, Gresham was subjected to test after test as she continued to lose weight. Finally, doctors close to her home in Rockford determined that she had cancer, and Gresham chose to have her care at the Kellogg Cancer Center.


Dr. Brockstein and the Kellogg team first hoped that the tumor could be removed by expert gastrointestinal surgeon Melissa Hogg, MD, but the tumor proved to be too involved with her nearby organs. The cancer was identified as a sarcoma, and Gresham began treatment to shrink it—but neither radiation nor chemotherapy worked.

“My family and I were just trying to accept that I was going to pass away from this cancer,” recalled Gresham. But molecular profiling of her tumor as part of the KCGI study successfully identified a genetic abnormality and a medication that could work for her. The KCGI team was able to get Gresham on the medication that in a matter of months began to shrink the tumor.

A CT scan this summer showed that the tumor was smaller. “For the first time, I had some good news. It was really the first hope I’ve had in over



Key members of the KCGI team Patient Financial Advocate Daphnee Silencieux (from left) Advanced Practice Nurse Gayathri Moorthy and Patient Financial Advocate Marissa Wiley provide invaluable help to patients navigating their cancer journey.



a year,” said Gresham. While the medication has left her feeling very tired, Gresham has been able to get off a feeding tube and move back to her own home after staying with family when she was so ill.

Dr. Brockstein is cautiously optimistic that the tumor will continue to shrink enough on the medication and can be removed surgically. Gresham will have another CT scan and meet with Dr. Hogg to talk about next steps.

“As of now, I’m just trying to stay as positive as I can,” said Gresham. Dr. Brockstein is one of the best

doctors I’ve ever had, and I know Dr. Hogg is a rock star. The care they’ve shown me is so important.”

“It’s so gratifying to help patients like Chantay with the collaborative team involved in the KCGI and her care,” said Dr. Brockstein. “Having molecular testing available for a cancer that’s so rare, like hers, is a huge benefit to our patients.”

“At one point, I didn’t even have a future to contemplate,” said Gresham, “and now I’m just looking forward to living my life.”



# Pharmacogenomic Testing Supports Individualized Care

NorthShore's comprehensive pharmacogenomics program continues to grow and now includes testing panels that offer guidance for nine chemotherapy medications and more than 40 medications used in supportive care. KCGI patients


receive pharmacogenomic testing in addition to targeted molecular testing of their tumor samples.

Beyond guidance on nausea and pain management, pharmacogenomics can provide significant value to cancer

patients by assisting with therapeutic selection of psychiatry medications, including antidepressants.

A recent pilot program led by Senior Clinical Specialist Dyson Wake, PharmD, incorporated pharmacogenomics testing in initial laboratory orders for new oncology patients treated with one of three specific chemotherapy drugs. During the two-month pilot involving select oncologists, patients with potential sensitivity to their planned chemotherapy regimens were identified, and discussion is now underway to expand the program.

The pharmacogenomics team's knowledge base and expertise provide vital clinical support. In the past year, the team published four articles, an abstract and had three posters accepted and graduated its inaugural resident. The resident is a key team member who helped investigate potentially targetable variants and presented patients at regular tumor board meetings.



Senior Clinical Specialist Dyson Wake (left) and Kellogg Cancer Genomic Initiative (KCGI) Advanced Practice Nurse Annette Sereika review pharmacogenomics testing for new oncology patients.

## Bioinformatics and Molecular Pathology Revolutionizing Treatment

As next-generation DNA sequencing (NGS) has quite literally revolutionized medicine with widespread testing for genomic anomalies and polymorphisms, the need for managing large amounts of data and interpreting results has created new challenges and opportunities. Flype is a web-based bioinformatics platform developed at NorthShore that incorporates the data from NGS into workflows, making it usable for clinicians. NorthShore's Center for Bioinformatics and Computational Biology team led by Director Larry Helseth, PhD, helps the molecular pathology team interpret DNA sequence results and then creates reports that are sent for oncologists' review.

"We use Flype to help organize patient results and interpretations for molecular tumor boards where advanced practice nurses, pharmacists, oncologists, pathologists and bioinformaticians meet virtually to review each patient's case and see how best to tailor their treatment to the molecular markers identified in their tumors," said Dr. Helseth. "The days of treating cancer based on the origin of the tumor are long gone."

Flype is also used to help integrate molecular test results from NorthShore and external facilities and match that data to patient outcomes to gain insight into treating future patients with specific molecular markers.


# Addressing Health Disparities

## Closing the Health Equity Gap in Breast Cancer Screening

Improving health equity for our patients and the communities we serve is an ongoing commitment for NorthShore and the focus of collaborative teamwork. After identifying a breast cancer screening disparity using a Lens of Equity tool developed by our analytics team, the Breast Health Center, Patient Care Center, analytics and Health Equity Impact Team (HEIT) worked together to drive improvement in screening rates.


Low screening rates for non-white and lower-income patients increased their risk for a delayed breast cancer diagnosis. The team worked to streamline mammography services and improve access for vulnerable populations. Frontline team members called close to 1,000 patients and helped schedule nearly 200 additional screenings to date.

The HEIT brought on a dedicated health equity community liaison to perform continued outreach and help patients navigate breast cancer screenings. We continue to work to close the health equity gap for breast cancer screening.



Community Liaison Diana Alvarez

### Breast Cancer Screening Compliance



## Using Genomics to Target High Rates of Prostate Cancer in Black Men



Dr. Brian Helfand

Prostate cancer is one of the most common forms of cancer, and studies show that inherited factors account for 57% of the risk for developing prostate cancer. Black men have a substantially higher incidence of prostate cancer and higher related death rates than the general population. A genomics program led by Brian Helfand, MD, PhD, the Ronald L. Chez Family and Richard Melman Family Endowed Chair of Prostate Cancer, has specifically focused on the high prevalence of prostate cancer in Black men. Dr. Helfand authored

an article in the *Clinical Leader* newsletter highlighting NorthShore's successful program and encouraging more protocols and interventions that promote the inclusion of diverse populations.

"Genomics research is shaping the future of prostate cancer and medicine at large," stated Dr. Helfand. "To improve health equity and benefit society, it's important that the diversity of patients taking advantage of clinical genomics is reflected in our clinic strategies."



## Subspecialty Expertise Attacks Rare Cancer

**B**ile duct cancers—also called cholangiocarcinoma—are rare, affecting fewer than six people in 100,000 according to the National Cancer

Institute. When 75-year-old Gerald Gray, DDS, was diagnosed in early 2022, he quickly appreciated the benefits of a sub-specialty group like the team at the Kellogg Cancer Center who successfully treated his cholangiocarcinoma.

Symptoms that initially mimicked gallbladder trouble began Dr. Gray's "whirlwind" of a cancer journey. General surgeon John Linn, MD, ordered a special MRI—called a magnetic resonance cholangiopancreatography—to provide detailed images of the hepatobiliary and pancreatic systems. Dr. Gray was admitted the same day and referred to expert oncology surgeon Melissa Hogg, MD, who reviewed his images while she was out of town to confirm the diagnosis.


He then had an endoscopic retrograde cholangiopancreatography (ERCP) with gastroenterologist Shailesh Bajaj, MD, who specializes in advanced therapeutic endoscopy and pancreaticobiliary disease, before having surgery with Dr. Hogg, who removed the tumor, bile duct, gallbladder and area lymph nodes.

"I was scheduled for a doctor's office visit, and within two days I had the visit consult, an MRCP, an ERCP with stent placement and an appointment to see a surgeon two days after discharge," said Dr. Gray. "The NorthShore system worked seamlessly, and I had five-star treatment all the way around."

A retired endodontist, Dr. Gray and his wife, who is a retired surgical nurse, both have a medical background and were more than impressed with the expert and compassionate care he received. Following his surgery, Dr. Gray had a consult for a second



Oncologist Dr. Robert Marsh (left) and surgeon Dr. Melissa Hogg provide collaborative care for patients with complex, advanced cancers.



opinion at Mayo Clinic and was told he was fortunate to have an oncology surgeon with the advanced skills of Dr. Hogg.

Following surgery, Dr. Gray began treatment with oncologist Robert Marsh, MD, who recommended both chemotherapy and radiation, the best protocol for beating the rare cancer.

"I feel fortunate to have Dr. Marsh in charge of my care—five stars again," said Dr. Gray, who also had high praise for radiation oncologist Arif Shaikh, MD. "All of these physicians, the speed with which care has been provided, the professional care and expertise given to me have saved my life," added Dr. Gray.

"He's done very well with the treatment, and all indicators are quite positive now," said Dr. Marsh, who will continue to closely monitor

Dr. Gray with scans and bloodwork for the next few years. While he initially had some serious side effects with the chemotherapy, Dr. Gray said Dr. Marsh and his team managed them quickly, adjusting doses and offering therapeutic options. Dr. Gray's last scan in October was clear.

"It truly is a team effort across so many disciplines to get patients like this through a complex regimen," said Dr. Marsh.

Dr. Gray considers himself blessed to be married to Susan, his wife of 46 years, for "all her sacrifices through this cancer journey and being the best advocate I could ever have." He is grateful to the entire Kellogg Cancer team of nurses, Advanced Practice Providers and more. "They save lives. That's what they do," said Dr. Gray. "I'm living a very blessed life."

## Expanded Services for Swedish Hospital Patients

More subspecialty expertise is now available for patients at Swedish Hospital with additional surgeons and medical oncologists joining the team and others adding clinic hours at the NorthShore campus in the city.

In addition to the growing roster of subspecialty physicians providing care, more robust support services are also part of the Swedish Hospital cancer team. Patients have access to a specially trained dietitian, social worker, psychologist and patient financial advocate for practical and emotional support and services throughout their cancer journey.

Patient assistance grants continue to support the integrated cancer care program with fundamental fitness and complementary treatments offered through the Galter LifeCenter.

A new Scheduling Coordinator program modeled after the Kellogg Cancer Center program provides an additional point person to help patients better navigate what can feel like an overwhelming number of appointments and next steps.

"As a physician, it's gratifying to be better able to serve our patients with a fully staffed team of nurses and social work and other services that are so valuable," said Swedish Hospital Cancer Center Medical Director Jeffrey Cilley, MD.

Plans to expand/renovate the physical space at Swedish Hospital will allow the cancer center to continue to grow with room for more subspecialists and more capacity to care for an increasing number of cancer patients in the community.

### Swedish Hospital New Specialist Coverage


- Sameer Alvi, MD**  
Otolaryngology, Head and Neck Cancers
- Hassan Arshad, MD**  
Otolaryngology, Head and Neck Cancers
- Elizabeth Burke, MD**  
Plastic Surgery/Breast Reconstruction
- Nicholas Campbell, MD**  
Lung Cancer, Esophageal Cancer, Head and Neck Cancers
- Jalal Damani, DO**  
Interventional Pulmonology, Lung Nodule Biopsy
- Melissa Hogg, MD, MS**  
Director, Liver and Pancreas Surgery
- Mary Tilley Jenkins Vogel, MD**  
Gynecologic Oncology
- Andrew Johnson, MD**  
Neurological Surgery, Brain and Spine Tumors
- Benjamin Johnson, MD**  
General Surgery, Minimally Invasive, Robotic Colon Cancer Surgery
- Daniel Laich, DO**  
Neurological Surgery, Spine Surgery, Spine Tumors
- Janette Maldonado, MD**  
General Surgery, Minimally Invasive, Robotic Colon Cancer Surgery
- Cecylia Mizera, MD**  
General Surgery, Breast Surgeon
- Elizabeth Poli, MD**  
Breast Surgeon
- Thomas (T.J.) Smith, MD, MS**  
Breast Surgeon
- Auddie Sweis MD**  
Otolaryngology, Nasal and Sinus Surgery, Skull Base Surgery

## Helping More Patients Quit Smoking

The Kellogg Cancer Center continues to expand its longstanding efforts to help patients quit smoking. Studies show that it is never too late to quit smoking to gain potential health benefits.


NorthShore now has more trained specialists with more dedicated time to see patients, especially those with a new cancer diagnosis. Kellogg is also participating in the Commission on Cancer "Just Ask" program, a national quality improvement project and clinical study. The initiative is designed to improve upon current smoking assessments by leveraging existing resources.

Every new cancer patient is asked about their smoking history. An automatic referral for an appointment with a tobacco cessation specialist is built into the electronic health record (EHR) for current smokers. Continued smoking/tobacco use after a cancer diagnosis decreases survival, reduces treatment efficacy and increases the risk of recurrence.



### Dr. Seth Krantz Honored with CoC Outstanding Performance Award

Thoracic Surgeon Seth Krantz, MD, was recognized by the Commission on Cancer (CoC) with one of its Cancer Liaison Physician (CLP) Outstanding Performance Awards. Ten CLP winners were chosen from more than 80 submissions, recognizing their hard work and dedication to improving the quality of care for cancer patients.



Dr. Seth Krantz

Among Dr. Krantz's many contributions noted in his nomination are his tireless efforts for the Kellogg Cancer Center's smoking cessation program. Dr. Krantz's leadership helped expand services through training additional tobacco treatment specialists at Mayo Clinic and establishing automatic referrals within the EHR for any new cancer patients identified as a smoker.

"He reminds patients that it's never too late to quit and that it often takes multiple attempts to quit for good. Dr. Krantz is a tried and true trailblazer for improvement," said his nomination.

"It's an honor to work with Dr. Krantz and to see his commitment to quality, safety improvement in the best interest of our patients and program," said Cancer Committee Nurse Coordinator Jamie Feld.



# Innovative Research Driving Clinical Excellence

## Personalized, Genetics-Based Prostate Cancer Care

A pioneering collaboration between NorthShore's Program for Personalized Cancer Care (PPCC) and Johns Hopkins University Department of Urology has the potential to transform prostate cancer care. Five new clinical studies will focus on hereditary risk, screening, biopsy and treatment by collecting and analyzing both germline and somatic DNA genetic data from several thousand prostate cancer patients. The prostate cancer team led by Brian Helfand, MD, PhD, and Jianfeng Xu, DrPH, Ellrodt-Schweighauser Family Chair of Cancer Genomic Research, has been supported by generous philanthropy as it works to further personalized prostate cancer screening and treatment strategies.

## Advancing Surgical Innovation

Accomplished oncoplastic breast surgeon Katherine Kopkash, MD, is a principal investigator in the first U.S. clinical trial of robotic assisted nipple-sparing mastectomies for women who are at high risk of developing breast cancer. NorthShore is the only Illinois site for this landmark study using the robotic



Dr. Katherine Kopkash

approach, which allows the entire operation to be performed through a 3.5 cm incision in the armpit. The procedure leaves patients with minimal scarring, the likelihood of more sensation and an easier recovery. "I'm excited to lead this trial that will provide surgeons with evidence-based data to support the expansion of this innovative new procedure," said Dr. Kopkash.

## Novel Pancreatic Cancer Screening

NorthShore is a regional leader in pancreas research, and our clinical pancreatic database is one of the largest in the country. A collaborative study with the University of Chicago focused on using novel genetic risk factors to identify subjects at high risk of developing pancreatic cancer and demonstrated the importance of genetic tools for screening. A new study in development will offer genetic testing for monogenic diseases and genetic risk scores for pancreatic cancer patients. First-degree relatives of patients identified as carriers will be offered genetic testing and consultation. This will be the first genetics-based pancreatic screening study in the country. The new study will be led by Mark Talamonti, MD, the Stanton and Margaret Rogers Palmer Chair of Surgery, and Jianfeng Xu, DrPH.



Dr. Mark Talamonti

## Improving Outcomes and Quality of Life

Philanthropic support is helping Katharine Yao, MD, Vice Chair for Research, Department of Surgery, lead innovative studies designed to help improve outcomes and quality of life for patients.

Educational mindfulness video modules targeting newly diagnosed patients, those undergoing treatment and survivors were developed as part of a novel mindfulness study. Patient responses and coping skills are now being documented and assessed after watching the videos.


Other studies are designed to support a proven, data-backed risk assessment score that would be given to all women undergoing screening mammography as part of a strategy to help prevent breast cancer. And a third initiative is looking at universal genetic testing for newly diagnosed breast cancer patients—specifically, how surgeons and clinicians collectively see the value in genetic testing.

"Supporting breast cancer research and women who face a devastating diagnosis, or carry genes that could become cancer, has been near and dear to my heart for years," said Mary Dillon President and CEO of Foot Locker, Inc., who is supporting Dr. Yao's research. "I've had a longstanding relationship with Dr. Yao. Her knowledge, passion and understanding of what it takes to prevent cancer and ensure the best possible outcomes are unmatched. These studies will move the needle toward more comprehensive screening, early detection and improving overall outcomes. The work she's doing is imperative in this age of genetics and mindfulness."



Dr. Katharine Yao

## Quick Diagnosis and Urgent Delivery Save Mom and Baby



Ashley Conley was 32 weeks pregnant with her fourth child when she started bruising all over and experiencing nose bleeds. At first, she assumed it was due to low iron in pregnancy, but then her gums began to bleed and Conley and her husband decided her unusual symptoms should be evaluated.

The 39-year-old mom had blood drawn on a Sunday and received a call before 6:30 a.m. the next day urging her to get to NorthShore Evanston Hospital immediately. Within minutes of her arrival, hematologist Amy Wang, MD, MPH, shared the devastating news that Conley had acute promyelocytic leukemia (APL) and that her baby would have to be delivered as soon as possible.


"Hours matter at this point," Conley was told. A comprehensive team of oncologists, maternal-fetal medicine experts and critical care specialists began meticulously planning the complex treatment and safe delivery of her baby. Conley's life-threatening condition put her at risk of severe bleeding and clotting complications while giving birth.

"The good news with APL is that it's highly curable if we get patients over the hump in the first month or two when mortality is highest," said Dr. Wang. "It was fortunate she was at 33 weeks and the obstetrics team was comfortable with the early delivery."

Conley was fortunate to have the hematology expertise to recognize the rare condition and the multidisciplinary, collaborative team that helped her deliver a healthy baby and fight the cancer. Conley was given her first round of ATRA (all-trans retinoic acid), an oral medication to treat APL, while still pregnant, as it is known to be safe for the baby.



Ashley Conley and her daughter Harlow survived a rare life-threatening cancer.



With her platelet levels dropping precipitously, Conley was transferred to the Intensive Care Unit, which was deemed the safest place for her to be induced and deliver her baby. A team of close to 30 clinicians—physicians, nurses, anesthesiologists and blood bank support—came together to manage her care and labor, and baby Harlow Rose was born on Feb. 9, 2022. Within an hour of giving birth, Conley was given her first intravenous chemotherapy treatment.

"She's really a tough person. She kept such a level head about everything going on," said Dr. Wang. "I think she

was in shock, but she trusted us. She was so strong and knew she *had* to be for her family."

Conley was hospitalized for a month to continue receiving chemotherapy that thankfully put her leukemia in remission. She completed several more months of outpatient treatment under Dr. Wang's direction to keep the APL in remission long enough to be cured. While it was an arduous journey, Conley is grateful for the exceptional care she received.

"Harlow is healthy and my boys love having a little sister," said Conley. "I am so thankful for everything."



# Comprehensive Support Services

*Thanks in part to our many generous donors, the Kellogg Cancer Center is able to provide patient- and family-centered care. In addition to an ongoing focus on prevention, early detection and advanced treatment options for cancer, we are also committed to offering patients and families a full range of resources to help navigate and manage their cancer journey.*

*From emotional and spiritual support to special nutritional guidance, integrative medicine services, and assistance with practical needs like transportation or financial aid, the extended Kellogg Cancer Center team delivers comprehensive, compassionate support.*

## Expanded Psychosocial Care

Generous funding from Carol Levy in memory of her husband Joseph enabled psychologist Elizabeth Kacel, PhD, to join the Kellogg Cancer Center team in late 2021. In her first year, Dr. Kacel completed nearly 800 patient visits, including new patient consultations and psychotherapy sessions. Treatment sessions focus on the use of evidence-based psychological approaches to improve cancer distress and optimize patients' quality of life during and beyond cancer.

"I am deeply moved by the caring and collaborative nature of the Kellogg Cancer Center team," said Dr. Kacel. "Every day is fast-paced and intense, yet slow and meaningful in how the team provides whole-person care. There's as much laughter as there are tears."

Providing expert psychological care from within the Kellogg Cancer Center offers many benefits for patients. The location is familiar, the stigma of mental health care is reduced and the role of psychological treatment during cancer is normalized.



Dr. Elizabeth Kacel (from left), Dr. Carol Rosenberg and Advanced Practice Nurse Anisha Patel collaborated on a powerful new lecture series for cancer survivors.

## Managing Fear of Recurrence and Progression

In collaboration with the Myra Rubenstein Weis (MRW) Living in the Future (LIFE) Cancer Survivorship Program led by Carol Rosenberg, MD, and Clinical Coordinator Anisha Patel APN, Dr. Elizabeth Kacel facilitated a new three-part "Evening of Survivorship" virtual summer lecture series. Fear of cancer recurrence or progression is one of the most common psychological concerns reported by patients diagnosed with all types and stages of cancer.

The series was designed to offer patients practical strategies for managing this specific concern in cancer survivorship. The series also featured contributions from the Kellogg team of oncology social workers. More than 200 participants—including patients, family members and healthcare providers—participated in the new series, which received exceptionally positive feedback.

## Vital Community Partnerships

Kellogg Cancer Center values its important partnerships and collaborations with community organizations dedicated to improving lives for cancer patients.

A longstanding partnership with the Cancer Wellness Center is a symbiotic relationship that helps provide cancer patients with additional psychosocial support and resources, as well as education on a variety of essential cancer-related topics.

The Cancer Wellness Center offers a range of services including educational programs, wellness classes, and support services in English and Spanish. Clinical services include individual, family and child counseling as well as support groups for men, women, young adults and anyone bereaved. Experts from NorthShore are tapped to speak at educational programs.

"The Center is a trusted source for evidence-based information to cancer patients and their loved ones," said Cancer Wellness Center Program Director Savina Chacheva. "The services are important as they allow patients to receive individualized support, reduce feelings of stress and improve overall wellbeing."

The American Cancer Society (ACS) supports many different programs benefiting cancer patients throughout the Chicago and northwest suburban region, including providing vital grants for transportation to and from facilities like Kellogg Cancer Center to address one of the key social determinants of health.



Dr. Carolina Soto Chervin

The ACS also partners with NorthShore in outreach and educational events, including a series of Facebook live events for Spanish speakers with NorthShore physicians like Carolina Soto Chervin, MD. "Seeing a physician speaking Spanish builds important trust for many patients," said ACS Cancer Support Strategic Partnerships Manager Aubree Thelen. "We're happy to partner with NorthShore and the boots-on-the-ground team of providers. This has been a really successful, consistent partnership. We share a mutual desire to find new ways to innovate and support patients."

## Donors Support Patient Care



Oncology Nurse Ann Puglisi with neuropathy kits now offered to cancer patients through the generous donation from The Kindness Fund.

## Research Award Supports Work with Young Cancer Survivors



Dr. Amy Wang

Hematologist Amy Wang, MD, MPH, earned a NorthShore Auxiliary Research Scholar Award for her work aimed at improving the quality of life for adolescents and young adults (AYA) with blood cancers. AYA blood cancer survivors are a vulnerable group experiencing high rates of morbidity and early mortality, and Dr. Wang designed and implemented a study during her fellowship training looking at severe symptoms and late effects of therapy for this population. The study was presented at the 2021 and 2022 American Society of Clinical Oncology meetings.

The Auxiliary grant will support Dr. Wang's efforts to establish a continuity clinic for high-risk survivors of pediatric and AYA cancers and to further her studies related to neurocognitive outcomes in AYA blood cancer survivors. Work on the continuity clinic will be a collaborative effort with the Kellogg team and Carol Rosenberg, MD, Director of the MRW LIFE Cancer Survivorship Program.

"I am grateful to the Auxiliary for this award, which is helping bring my vision to fruition and serving a vulnerable patient population," said Dr. Wang, who will use preliminary data from the study to apply for external funding to help design multi-institutional and cooperative group studies.



## Oncology Trials

### Breast Cancer

**EA1181** Compass (HER2-pCR): Perioperative THP and postoperative HP in patients who achieve a pathologic complete response

**A011801** The CompassHER2 trials (COMprehensive use of Pathologic response ASSESSment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

**S2007** A Phase II Trial of Sacituzumab Govitecan (IMMU-132) for Patients with HER2-Negative Breast Cancer and Brain Metastases

### Gastrointestinal Cancer

**NRG-GI004/SWOG-S1610** Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

**UC14-0594** Perioperative FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

**A221805** Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

**NRG-GI005** Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Stage IIA Colon Cancer (COBRA) (NCT #TBD)

### Genitourinary Cancer

**PCCTC c16-168** A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

**Johns Hopkins J1557** Overcoming Drug Resistance in Metastatic Castration-Resistant Prostate Cancer with Novel Combination of TGF- $\beta$  Receptor Inhibitor LY2157299 and Enzalutamide: A Randomized Multi-Site Phase II Study

**Genomic Profiling** Genomic Profiling and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer

**NRG-GU008** A Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)

**EA8183** A Phase III Study of Early Intervention after RADICAL Prostatectomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

**UC13-0540** Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer

**AVEO-TiNivo-2** A Phase III, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor

**S1806** Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

**S2011** Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma—SWOG GAP trial

**CURLu177PSM0001** A Multi-Center, Open-Label, Randomized Phase III Trial Comparing the Safety and Efficacy of 177L-PSMA-I&T Versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

### Gynecologic Cancer

**AGCT1531** A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors

**GOG-3026** A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum NRG-GY020: Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

**NRG-CC008** A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCK)

**NRG-GY019** A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

**NRG-GY022** Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin

**NRG-GY023** A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI 4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

**NRG-GY012** A Randomized Phase II Study Comparing Single-Agent Olaparib, Single-Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), and Olaparib/AZD5363 (Capiwasertib) in Women with Recurrent, Persistent, or Metastatic Endometrial Cancer: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer

## Oncology Trials

### Head and Neck Cancers

**HCN** Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

**Merck 3475-689** A Phase III Randomized, Open-Label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

**EA3163** Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Postoperative Radiation Versus Surgery and Postoperative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma

**NRG HN005** A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking-Associated Oropharyngeal Cancer

**RTOG 1216** Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

**MNPR-301-001** A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Patients with Oropharyngeal Cancer

### Hematology

**Connect<sup>®</sup> MDS/AML** The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

**CIBMTR** Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

**A041501** A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)

**EAA173** Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

**S1925** Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

**EA9181** A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

**A041701** A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

**EA4181** A Randomized 3-Arm Phase II Study Comparing 1) Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma

### Lung Cancer

**Lung-MAP** A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer

**E4512** A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

**A151216** Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

**EA5181** Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

**A081801** Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)

**PrECOG 0506** Durvalumab (MEDI4763) with chemotherapy as first line treatment in advanced pleural mesothelioma: a phase III randomized trial

**S1900E** A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer

### Neuro Oncology

**NRG BN003** Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

**A071702** A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hypermutated Recurrent Glioblastoma

**NCI-Connect Nivolumab Rare CNS Trial 17-C-0102** Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

**Brain-Up/U of C** A Phase I Study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter[1] Methylated IDH Wildtype Glioblastoma

### Sarcoma

**Ayala AL-DES-01 (Ringside)** A Phase II/III, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

### Skin Cancer

**EA6141** Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

**Regeneron Cemiplimab Survivorship Epidemiology (CASE) Study**

### Other

**Carevive OPT-IN<sup>®</sup>** Real-World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute Myelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring

**A151804** Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

**Genomic Panels** Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer

For more information about clinical trials, visit [northshore.org/kellogg-cancer-center/clinical-trials](http://northshore.org/kellogg-cancer-center/clinical-trials)



## Surgical Oncology Trials

## Breast Surgery

**EH20-166** The Ergonomic Effects of the Robotic Nipple-Sparing Mastectomy on the Operating Surgeon

**EH20-165** Exploring Breast Surgical Oncologists' Attitudes and Comfort Level with Universal Genetic Testing

**EH15-297** A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy—Alliance A011202

**EH20-167** Breast Cancer Stem Cells and Peritumoral Adipose Tissue

**EH21-214** The Impact of Breast Cancer Surgical Delays Brought on by the Initial COVID-19 Pandemic Surge on Final Pathologic Tumor Stage

**EH17-072** Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS

**EH17-209** Genetic Determinants of Cooperative Interactions on Breast Cancer Intratumor Heterogeneity

**EH18-243** Tell Me Where It Hurts: The Ergonomic Effects of Mastectomies on the Operating Surgeon

**EH10-081-ACOSOG Z1071** A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis

**EH88-077** The Establishment and Maintenance of the NorthShore University HealthSystem Comprehensive Data Registry for Breast Surgeries and Breast Tissue Bank

**EH20-301** WhySurg for Men: A Male Breast Cancer Survey for Men with Breast Cancer

**EH20-303** The WhySurg Study for Men with Breast Cancer: The Physician Perspective

**EH20-171 CROWN Study** COVID-19-Related Oncologists' Concerns about Treatment Delays and Physician Wellbeing

**EH19-074** A Prospective, Multicenter Investigation of the da Vinci Xi Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures

**EH20-348** Retrospective, Multicenter Study of Open Nipple-Sparing Mastectomy (NSM)

**EH20-134** The PREPARE Study: Supporting Women with Breast Cancer to Prepare for Treatment

**EH20-195** Outcomes of COVID-19 Positive Cancer Patients Compared to Patients without Cancer: A Single Institution Experience

## Colorectal Surgery

**EH12-468 N1048** A phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

## Head and Neck Surgery

**EH17-116** Lipid Tissue from Head and Neck Cancer

## Pancreatic Cancer

**EH18-265** A Phase III Multicenter, Open-Label, Randomized, Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreaticoduodenectomy

**EH08-197T** Clinical pancreatic cancer database

**EH13-433** Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology

**EH02-186** The Pancreatic Sample Repository

**EH17-132** Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreaticoduodenectomy, and Efficacy of Pharmacologic Prophylaxis

**EH21-215** Extended Post-Operative Thromboprophylaxis After Pancreatic Resection for Pancreatic Cancer is Associated with Decreased Risk of Venous Thromboembolism in the Minimally Invasive Approach

**EH21-099** Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

## Lung and Esophageal Cancer

**EH98-136** Establishment and maintenance of a comprehensive thoracic tumor data registry and biorepository

**EH18-162** Inherited Cancer Panel Performance in Predicting Outcomes Among Patients Diagnosed with Lung Cancer

**EH16-356** Clinical Characteristics of Anti-PD-1/PD-L1 Relapses in Non-Small Cell Lung Cancer (NSCLC)

**EH16-079** Retrospective chart review study to look at adequacy of lymph node staging in patients undergoing curative anatomic resection for non-small cell lung cancer

**EH16-362** Natural History of Indeterminate Lung Nodules

**EH20-111** Non-Small Cell Lung Cancer Tissue Sample Study

## Thyroid Surgery

**EH14-058** The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

## Genitourinary Cancer

**EH09-043** A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

**EH13-250** Cancer susceptibility: The ICPG study (International Consortium for Prostate Cancer Genetics)

**EH13-446** A retrospective review of patients who have been removed from study EH09-043: A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

**EH14-361 SPORE Project 1** Impact of Germline Genetic Variants and Failure of Active Surveillance for Prostate Cancer

**EH14-133** The Lived Experience of Men with Sexual Dysfunction After Prostate Cancer Treatment

**EH15-124** Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination through Engagement in Mindfulness Education (REASSURE ME)

**EH16-202** Detecting copy number alterations (CNAs) of MYC and PTEN in biopsy samples to predict clinical outcomes in prostate cancer

**EH16-239** The impact of using genetic risk scores (GRSs) for inherited risk assessment of prostate cancer

**EH16-183** Evaluation of the utility of the prostate health index in routine clinical practice

**EH15-365** Assessing the Clinical Utility of Genetic Risk Scores for Targeted Cancer Screening

**EH18-381** A Randomized Phase III, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer

**EH20-278** A prospective, phase III, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer


**EH20-318** A prospective, phase III, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

**EH14-206** Nanocytology to mitigate overdiagnosis of prostate cancer

**EH16-232** Trends in upper tract urothelial treatment

**EH16-240** Timing of artificial urinary sphincter placement

**EH16-387** Risk-Stratification of Prostate Cancers via Field Carcinogenesis Nanocytology



## 2022 Research Publications

Ahmad SB, Rice M, **Chang C**, Hamad A, Kingham TP, He J, Pimiento JM, Zureikat AH, Zeh HJ 3rd, **Hogg ME**. Will It Play in Peoria? A Pilot Study of a Robotic Skills Curriculum for Surgical Oncology Fellows. *Ann Surg Oncol*. 2021 Oct;28(11):6273-6282. doi: 10.1245/s10434-021-09913-z. Epub 2021 Mar 31. PMID: 33791900

Ahmad SB, Rice M, **Chang C**, Zureikat AH, Zeh HJ 3rd, **Hogg ME**. dV-Trainer vs. da Vinci Simulator: Comparison of Virtual Reality Platforms for Robotic Surgery. *J Surg Res*. 2021 Nov; 267:695-704. doi: 10.1016/j.jss.2021.06.036. Epub 2021 Aug 1. PMID: 34348185

Akmatbekov A, **Saha P**, **DePersia A**, and Sullivan M. Predicted and Genomic Risk in ER+ Invasive Breast Cancer in BRCA Mutation Carriers. Poster presented at United States and Canadian Academy of Pathology 2022 Annual Meeting. March 2022. Los Angeles, California.

Al Abbas AI, Hamad AB, Zenati MS, Zureikat AH, Zeh HJ 3rd, **Hogg ME**. Does CT scanning after pancreaticoduodenectomy reduce readmission rates: an analysis of 900 resections at a high-volume center. *HPB (Oxford)*. 2022 Jul 1: S1365-182X(22)01512-X. doi: 10.1016/j.hpb.2022.06.012. Online ahead of print. PMID: 35871133

Al Abbas AI, **Wang C**, Hamad AB, Knab LM, Rice MK, Moser AJ, Zeh HJ 3rd, Zureikat AH, **Hogg ME**. Mentorship and formal robotic proficiency skills curriculum improve subsequent generations' learning curve for the robotic distal pancreatectomy. *HPB (Oxford)*. 2021 Dec;23(12):1849-1855. doi: 10.1016/j.hpb.2021.04.022. Epub 2021 May 5. PMID: 34059420

AlMasri S, Zenati M, Hammad A, Nassour I, Liu H, **Hogg ME**, Zeh HJ, Boone B, Bahary N, Singhi AD, Lee KK, Paniccia A, Zureikat AH. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. *JAMA Netw Open*. 2022 Jun 1;5(6): e2218355. doi: 10.1001/jamanetworkopen.2022.18355. PMID: 35737385

Autio KA, Antonarakis ES, Mayer TM, **Shevrin DH**, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. *Eur Urol Open Sci*. 2021 Nov 17; 34:70-78. doi: 10.1016/j.euro.2021.09.015. eCollection 2021 Dec. PMID: 34934969

Bancroft EK, Page EC, Brook MN ... **Kaul K**, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. *Lancet Oncol*. 2021 Nov; 22(11):1618-1631. doi: 10.1016/S1470-2045(21)00522-2. Epub 2021 Oct 19. PMID: 34678156

**Barnea Stonim L**, **Alikhan M**, **Reddy K**, **Joseph N**, **Mangold KA**, **Sabatini L**, **Kaul KL**. Cell-Free Nucleic Acids in Cancer: Current Approaches, Challenges, and Future Directions. Chapter 14, *Advances in Molecular Pathology*, 4:187-198; Elsevier, 2021 Nov. doi: https://doi.org/10.1016/j.yamp.2021.07.007. (https://www.sciencedirect.com/science/article/pii/S2589408021000156)

Bleicher RJ, Moran MS, Ruth K, Edge SB, Dietz JM, Wilke LG, Stearns V, Kurtzman SH, Klein J, **Yao KA**. The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures. *Ann Surg Oncol*. 2022 Jan;29(1):469-481. doi: 10.1245/s10434-021-10512-1. Epub 2021 Jul 29. PMID: 34324114

**Boyle CA**, Ravichandran U, Hankamp V, Ilbawi N, Conway-Svec C, Shifley D, **Hensing T**, Kim S, **Halasyamani L**. Safe Transitions and Congregate Living in the Age of COVID-19: A Retrospective Cohort Study. *J Hosp Med*. 2021 Aug 18. doi: 10.12788/jhm.3657. Online ahead of print. PMID: 34424185

Brajcich BC, Benson AB, Gantt G, Eng OS, **Marsh RW**, Mulcahy MF, Polite BN, Shogan BD, Yang AD, Merkow RP. Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. *J Surg Oncol*. 2022 Mar;125(4):560-563. doi: 10.1002/jso.26758. Epub 2021 Nov 25. PMID: 34820843

Broyles JM, Liao EC, Kim J, Heistain J, **Sisco M**, Karp N, Lau FH, Chun YS. Acellular Dermal Matrix-Associated Complications in Implant-Based Breast Reconstruction: A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Two Human Tissues. *Plast Reconstr Surg*. 2021 Sep 1;148(3):493-500. doi: 10.1097/PRS.0000000000008194. PMID: 33877063

**Caplan A**, **Bates KW**, **Brioni C**, **Santos A**, **Sabatini LM**, **Kaul KL**, Carnethon MR, **Khandekar JD**, Greenland P. Clinical characteristics and viral load dynamics of COVID-19 in a mildly or moderately symptomatic outpatient sample. *PLoS One*. 2021 Oct 21;16(10): e0258970. doi: 10.1371/journal.pone.0258970. eCollection 2021. PMID: 34673816

**Chichura A**, Attai DJ, **Kuchta K**, **Nicholson K**, **Kopkash K**, **Pesce C**, **Yao K**. ASO Visual Abstract: Male Breast Cancer Patients and Surgeon Experience: The Male WhySurg Study. *Ann Surg Oncol*. 2022 Oct;29(10):6132. doi: 10.1245/s10434-022-12218-4. PMID: 36001182

**Chichura A**, Attai DJ, **Kuchta K**, **Nicholson K**, **Kopkash K**, **Pesce C**, **Yao K**. Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study. *Ann Surg Oncol*. 2022 Oct;29(10):6115-6131. doi: 10.1245/s10434-022-12135-6. Epub 2022 Jul 25. PMID: 35876929

Chopra A, Zenati M, **Hogg ME**, Zeh HJ 3rd, Bartlett DL, Bahary N, Zureikat AH, Beane JD. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. *Ann Surg Oncol*. 2021 Nov;28(12):7759-7769. doi: 10.1245/s10434-021-10175-y. Epub 2021 May 23. PMID: 34027585

Collins K, Hwang M, Antic T, **Paintal A**, Argani P, Matoso A, et al. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma. *Histopathology*. 2022 Jul 30. doi: 10.1111/his.14731. Online ahead of print. PMID: 35971742

Cordova R, Kiekens K, Burrell S, Drake W, Kmeid Z, Rice P ... **Rodriguez GC**, et al. Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. *J Biomed Opt*. 2021 Jul;26(7):076001. doi: 10.1117/1.JBO.26.7.076001. PMID: 34216135

**Deliere A**, Attai D, Victorson D, **Kuchta K**, **Pesce C**, **Kopkash K**, **Sisco M**, **Seth A**, **Yao K**. Patients Undergoing Bilateral Mastectomy and Breast-Conserving Surgery Have the Lowest Levels of Regret: The WhySurg Study. *Ann Surg Oncol*. 2021 Oct;28(10):5686-5697. doi: 10.1245/s10434-021-10452-w. Epub 2021 Aug 25. PMID: 34432189

**Deliere A**, Attai D, Victorson D, **Kuchta K**, **Pesce C**, **Kopkash K**, **Sisco M**, **Seth A**, **Yao K**. Patients Undergoing Bilateral Mastectomy and Breast-Conserving Surgery Have the Lowest Levels of Regret: The WhySurg Study. *Breast Cancer Res Treat*. 2021 Apr;186(3):625-635. doi: 10.1007/s10549-021-06101-1. Epub 2021 Jan 31. PMID: 33517522

**Deliere AE**, **Kuchta KM**, **Pesce CE**, **Kopkash KA**, **Yao KA**. Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. *J Am Coll Surg*. 2022 Nov 1;235(5):788-798. doi: 10.1097/XCS.0000000000000326. Epub 2022 Oct 17. PMID: 36102573

**DeLuna H**, Velikov D, **Patel H**, **Feld J**, **Robin J**, **Rosenberg C**, and **Saha P**. Improving cardiac monitoring in early-stage breast cancer patients receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. Poster presented at ASCO Quality Care Symposium. September 2022. Chicago, IL.

Derman BA, Kansagra A, Zonder J, Stefka AT, **Grinblatt DL**, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasieliec J, Jakubowiak AJ, Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. *JAMA Oncol*. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. PMID: 35862034

Diebolt JH, Yu KM, Wood S, Ziegler A, France A, Villwock MR, **Alvi SA**, Kakarala K, Shnyder Y, Gan GN, Lominksa CE, Neupane P, Bur AM. Prognostic Implications of Skin Invasion in Locally Advanced Oral Cavity Squamous Cell Carcinoma. *Otolaryngol Head Neck Surg*. 2022 Aug 2;1945998221116746. doi: 10.1177/01945998221116746. Online ahead of print. PMID: 35917167

Ecanow N, **Chichura A**, **Kopkash K**, **Pesce CE**, Sullivan M, **Yao K**. Gestational gigantomastia complicated by breast infarctive necrosis in the setting of COVID-19 infection: a case report. *Ann Breast Surg*. Accepted April 2022

Expert Panel on Breast Imaging, Weinstein SP, Slanetz PJ, Lewin AA, Battaglia T, Chaggar AB, Dayaratna S, Dibble EH, Goel MS, Hayward JH, Kubicky CD, Le-Petross HT, Newell MS, Sanford MF, Scheel JR, Vincoff NS, **Yao K**, Moy L. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. *J Am Coll Radiol*. 2021 Nov;18(11S):S456-S473. doi: 10.1016/j.jacr.2021.09.002. PMID: 34794600

*continued >*

For more information about clinical trials, visit [northshore.org/kellogg-cancer-center/clinical-trials](https://northshore.org/kellogg-cancer-center/clinical-trials)



Fei N, Wen S, Ramanathan R, **Hogg ME**, Zureikat AH, Lotze MT, Bahary N, Singhi AD, Zeh HJ, Boone BA. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. *Clin Transl Sci*. 2021 Sep;14(5):1822-1829. doi: 10.1111/cts.13029. Epub 2021 May 18. Clinical Trial. PMID: 34002944

**Ferral H, Alonzo MJ**, Datri J, **Hogg ME, Marsh R, Talamonti MS**. Endovascular management of portal vein obstruction in hepatobiliary cancer patients. *J Surg Oncol*. 2022 Mar;125(3):392-398. doi: 10.1002/jso.26713. Epub 2021 Oct 13. PMID: 34643276

**Ferral H, Fimmel CJ**, Sonnenberg A, **Alonzo MJ, Aquisto TM**. Transjugular liver biopsy with hemodynamic evaluation: correlation between hepatic venous pressure gradient and histologic diagnosis of cirrhosis. *J Clin Imaging Sci*. 2021 Apr 26; 11:25. doi: 10.25259/JCIS\_233\_2020. eCollection 2021. PMID: 33948340

**Fimmel CJ, Khan MQ, Belopolsky Y, Imas P, Gampa A**, Sonnenberg A. Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program. *J Viral Hepat*. 2021 Aug;28(8):1200-1205. doi: 10.1111/jvh.13524. Epub 2021 May 7. PMID: 33896092

Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, ... **Rodriguez GC**, et al. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. *Commun Biol*. 2022 Oct 6;5(1):1061. doi: 10.1038/s42003-022-03978-6. PMID: 36203093

**Helseth DL Jr, Gulukota K, Miller N, Yang M, Werth T, Sabatini LM, Bouma M, Dunnenberger HM, Wake DT, Hulick PJ, Kaul KL, Khandekar JM**. Flype: Software for enabling personalized medicine. *Am J Med Genet C Semin Med Genet*. 2021 Mar;187(1):37-47. doi: 10.1002/ajmg.c.31867. Epub 2020 Dec 3. PMID: 33270363

**Hensing TA**, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Fallor BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients with Metastatic NSCLC. *JTO Clin Res Rep*. 2021; 2:100208. Published online 13 July 2021. <https://doi.org/10.1016/j.jtocrr.2021.100208>

Herrmann AC, Hanau C, Karcher D, Miller DC, Murtha A, Sanders AE, Timmons C, **Kaul KL**. The Pathology Fellowship Application Crisis: The current state and suggestions for remediation. *Acad Pathol*. 2022 Jun 25; 9(1):100029. doi: 10.1016/j.acpath.2022.100029. eCollection 2022. PMID: 35782704

**Holoubek SA, MacKinney EC, Khokar AM, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA**. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm. *Surgery*. 2022 Jan;171(1):203-211. doi: 10.1016/j.surg.2021.05.054. Epub 2021 Aug 10. PMID: 34384604

**Holoubek SA, MacKinney EC, Khokar AM, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA**. Treatment Differences for Adrenocortical Carcinoma by Race and Insurance Status. *J Surg Res*. 2022 Aug 17; 280:169-178. doi: 10.1016/j.jss.2022.05.011. Online ahead of print. PMID: 35987166

Huang A, **Sisco M**, Kuchta K, Alva D, Seth A. Wise-pattern Mastectomy with Inferior Dermal Sling: A Viable Alternative to Elliptical Mastectomy in Prosthetic Based Breast Reconstruction. *Plastic and Reconstructive Surgery*. In press

Joung RH, Nelson H, Mullett TW, Kurtzman SH, Shafir S, Harris JB, **Yao KA**, Brajcich BC, Bilimoria KY, Cance WG. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic. *Cancer*. 2022 Jun 1;128(11):2119-2125. doi: 10.1002/cncr.34157. Epub 2022 Mar 21. PMID: 35307815

Kantor O, **Chang C, Yao K**, Boughey J, Roland C, Francescatti AB, Blair S, Dickson Witmer D, Hunt KK, Nelson H, Weiss A, Oseni T. Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers. *Ann Surg Oncol*. 2021 Sep;28(9):4995-5004. doi: 10.1245/s10434-020-09533-z. Epub 2021 Jan 9. PMID: 33423122

Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, **Marsh R**, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Efficacy of Preoperative mFOLFIRINOX versus mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. *JAMA Oncol*. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319. PMID: 35834226

**Kaul KL**. The Molecular Genetic Pathology Fellowship Curriculum: Time for Evolution? *J Mol Diagn*. 2022, in press. 2022 Aug;24(8):823-824. doi: 10.1016/j.jmoldx.2022.04.012. Epub 2022 Jun 8. PMID: 35688356

**Kaur A, Kuchta K, Watkin W, Sullivan M, Liu L, Jamshidi P, Campbell N, Brockstein B, Paintal A**. Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. *Arch Pathol Lab Med*. 2022 Jul 21. doi: 10.5858/arpa.2021-0464-OA. Online ahead of print. PMID: 35862863

**Khan MQ, Belopolsky Y, Gampa A, Greenberg I, Beig MI, Imas P, Sonnenberg A, Fimmel CJ**. Effect of a best practice alert on birth-cohort screening for Hepatitis C virus. *Clin Transl Gastroenterol*. 2021 Jan 12; 12(1):e00297. doi: 10.14309/ctg.000000000000297. PMID: 33522731

**Kopkash K, Novak K**, Murphy R, **Deliere A, Kuchta K, Rabbitt S, Pesce C, Winchester D, Yao K**. Improving the Breast Surgeon's Ergonomic Workload for Nipple-Sparing Mastectomies Using Exercise and Operating Room Positioning Protocol. *Ann Surg Oncol*. 2021 Oct;28(10):5698-5706. doi: 10.1245/s10434-021-10447-7. Epub 2021 Jul 27. PMID: 34318384

Korrel M, Lof S, Alseidi AA, Asbun HJ, Boggi U, **Hogg ME**, Jang JY, Nakamura M, Besselink MG, Abu Hilal M; International Consortium on Minimally Invasive Pancreatic Surgery (I-MIPS). Framework for Training in Minimally Invasive Pancreatic Surgery: An International Delphi Consensus Study. *J Am Coll Surg*. 2022 Sep 1;235(3):383-390. doi: 10.1097/XCS.0000000000000278. Epub 2022 May 20. Review. PMID: 35972156

**Krantz SB, Zeeshan K, Kuchta KM, Hensing TA, Mangold KA, Zheng SL, Xu J**. Germline Mutations in High Penetrance Genes are Associated with Worse Clinical Outcomes in Patients with Non-Small Cell Lung Cancer. *JTCVS Open*. Accepted 2022 Sep

Liu JB, Tam V, Zenati MS, Schwartz D, Ali A, Low CA, Smith LJ, Zeh HJ 3rd, Zureikat AH, **Hogg ME**. Association of robotic approach with patient-reported outcomes after pancreatectomy: a prospective cohort study. *HPB (Oxford)*. 2022 Apr 26; S1365-182X(22)00103-4. doi: 10.1016/j.hpb.2022.04.008. Online ahead of print. PMID: 35568654

Liu L, Deng J, Cibull T, **Pesce CE**. Invasive breast cancer found in a patient with new-onset pemphigus foliaceus. *JAAD Case Rep*. 2021 Oct 23; 18:67-70. doi: 10.1016/j.jidcr.2021.10.014. eCollection 2021 Dec. PMID: 34841027

Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, **Kaminer LS**, Appelbaum FR, Larson RA, Tallman MS. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. *Leuk Res*. 2021 Dec; 111:106736. doi: 10.1016/j.leukres.2021.106736. Epub 2021 Oct 28. PMID: 34773794 Clinical Trial

**MacKinney EC, Holoubek SA, Khokar AM, Kuchta KM, Moo-Young TA, Prinz RA, Winchester DJ**. Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma. *Am J Surg*. 2022 Mar;223(3):582-586. doi: 10.1016/j.amjsurg.2022.01.004. Epub 2022 Jan 20. PMID: 35151433

**MacKinney EC, Kuchta KM, Winchester DJ, Khokar AM, Holoubek SA, Moo-Young TA, Prinz RA**. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2NOMO Stage I classic papillary thyroid cancer. *Surgery*. 2022 Jan;171(1):197-202. doi: 10.1016/j.surg.2021.08.025. Epub 2021 Oct 16. PMID: 34666913

Mai PL, Miller A, Black A, Falk RT, Boggess JF, Tucker K, Stuckey AR, **Rodriguez GC**, Wong C, Amatruda TT, Wilkinson KJ, Modesitt SC, Yamada SD, Bixel KL, Glaser GE, Rose PG, Greene MH, Sherman ME. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. *Am J Obstet Gynecol*. 2022 Jul; 227(1):e1-e11. doi: 10.1016/j.ajog.2022.02.022. Epub 2022 Feb 22. PMID: 35216968

Meyyappan T, Wilson GC, Zeh HJ, **Hogg ME**, Lee KK, Zureikat AH, Panizza A. Robotic approach mitigates the effect of major complications on survival after pancreaticoduodenectomy for periampullary cancer. *Surg Endosc*. 2022 Sep 26. doi: 10.1007/s00464-022-09638-4. Online ahead of print. PMID: 36163566

Miller DC, Karcher DS, **Kaul K**. The crisis in the pathology subspecialty fellowship application process: historical background and setting the stage. *Acad Pathol*. 2022, in press.

Mitzman B, Varghese TK Jr, **Kuchta K, Krantz SB**. National guideline concordance and outcomes for pathologic N2 disease in non-small cell lung cancer. *J Thorac Dis*. 2022 May;14(5):1360-1373. doi: 10.21037/jtd-21-1845. PMID: 35693597

Mullens CL, Van Horn AL, Marsh JW, **Hogg ME**, Thomay AA, Schmidt CR, Boone BA. Development of a Senior Medical Student Robotic Surgery Training Elective. *J Med Educ Curric Dev*. 2021 Jun 29; 8:23821205211024074. doi: 10.1177/23821205211024074. eCollection 2021 Jan-Dec. PMID: 34263057

Mungo B, Hammad A, AlMasri S, Dogeas E, Nassour I, Singhi AD, Zeh HJ 3rd, **Hogg ME**, Lee KKW, Zureikat AH, Panizza A. Pancreaticoduodenectomy for benign and premalignant pancreatic and ampullary disease: Is robotic surgery the better approach? *Surg Endosc*. 2022 Sep 22. doi: 10.1007/s00464-022-09632-w. Online ahead of print. PMID: 36138252

**Nelson OL**, Rosales R, Turbow JM, Thaete LG, Cline JM, **Rodriguez GC**. Progesterin Significantly Inhibits Carcinogenesis in the Mogg-TAg Transgenic Mouse Model of Fallopian Tube Cancer. *Cancer Prev Res (Phila)*. 2022 Feb;15(2):75-86. doi: 10.1158/1940-6207.CAPR-21-0324. Epub 2021 Nov 29. PMID: 34844992

Orloff LA, Noel JE, Stack BC Jr, Russell MD, Angelos P, Baek JH, ... **Karcioglu AS**, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society and Thyroid Nodules Therapies Association. *Head Neck*. 2022 Mar; 44(3):633-660. doi: 10.1002/hed.26960. Epub 2021 Dec 23. PMID: 34939714

**Paintal A** and Antic T. The emerging role of NF2 alterations in new and established subtypes of renal cell carcinoma. *Hum Pathol*. 2022 Jun 12; S0046-8177(22)00153-8. doi: 10.1016/j.humpath.2022.06.008. Online ahead of print. PMID: 35705112

**Paintal A**, Tjota MY, Wang P, Fitzpatrick C, Wanjarri P, Stadler WM, Gallan AJ, Segal J, Antic T. NF2-Mutated Renal Carcinomas Have Common Morphologic Features Which Overlap with Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. *Am J Surg Pathol*. 2022 May 1;46(5):617-627. doi: 10.1097/PAS.0000000000001846. PMID: 35034039

Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, **Grinblatt DL**, Komrokji RS, Kurtin SE, Maciejewski JP, Polyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol*. 2021 Jun;43(3):426-432. doi: 10.1111/ijlh.13400. Epub 2020 Nov 21. PMID: 33220019

**Peerenboom R, Ackroyd SA, Chang C, Moore ED, Vogel TJ, Lippitt MH, Rodriguez G, Kirschner CV**. Surviving and thriving: What do survivors of gynecologic cancer want? *Gynecol Oncol Rep*. 2022 May 26; 41:101011. doi: 10.1016/j.gore.2022.101011. eCollection 2022 Jun. PMID: 35663850

**Pesce C, Jaffe J, Kuchta K, Yao K, Sisco M**. Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy. *Breast Cancer Res Treat*. 2021 Jan;185(2):359-369. doi: 10.1007/s10549-020-05964-0. Epub 2020 Oct 8. PMID: 33033966 Randomized Controlled Trial

Peterson J, Rubio J, Pandey T, The SimBioSys team, **Saha P**. Validation of prognostic platform to further refine identification of high risk patients indicated for chemotherapy free treatment in early-stage breast cancer. Poster accepted at San Antonio Breast Cancer Symposium (SABCS). December, 2022. San Antonio, Texas.

Radi I, Tellez JC, Alterio RE, Scott DJ, Sankaranarayanan G, Nagaraj MB, **Hogg ME**, Zeh HJ, Polanco PM. Feasibility, effectiveness and transferability of a novel mastery-based virtual reality robotic training platform for general surgery residents. *Surg Endosc*. 2022 Oct;36(10):7279-7287. doi: 10.1007/s00464-022-09106-z. Epub 2022 Feb 22. PMID: 35194662

**Ramirez Barriga M, Rojas A**, Roggin KK, **Talamonti MS, Hogg ME**. Development of a Two-Week Dedicated Robotic Surgery Curriculum for General Surgery Residents. *J Surg Educ*. 2022 Jul-Aug;79(4):861-866. doi: 10.1016/j.jsurg.2022.02.015. Epub 2022 Mar 26. PMID: 35351431

**Resurreccion WK**, Hulsizer J, **Shi Z, Wei J, Wang CH, Na R, Zheng SL**, Struve C, **Helfand BT, Khandekar J, Billings LK, Caplan MS, Xu J**. Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the United Kingdom Biobank. *Am J Trop Med Hyg*. 2021 Jun 15;105(2):368-371. doi: 10.4269/ajtmh.20-1657. PMID: 34129519

Rifkin AS, Less EM, Wei J, Shi Z, **Zheng SL, Helfand BT, Hulick PJ, Krantz SB, Xu J**. Association of reported monogenic genes with lung cancer risk. Manuscript under review. 2022 Sep

**Rojas A, Paterakos P, Talamonti MS, Hogg ME**. Robotic ampullectomy for benign tumors: A video technique demonstration. *Cir Esp (Engl Ed)*. 2022 May 1; S2173-5077(22)00092-8. doi: 10.1016/j.cireng.2022.04.017. Online ahead of print. PMID: 35508297

**Rosenberg CA, Saha P, DeLuna H, Velikov D, Patel H, Feld J, Robin J**: Improving cardiac monitoring in patients with early-stage breast cancer receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. Sep 2022: *J Clin Oncol*, 2022 (suppl 28; abstr 191)

Russell MD and **Silver Karcioglu A**. Thyroid Cancer Survivorship: The Patient Experience. Accepted for publication in the invited special series "Improved Quality of Life after Thyroid Surgery." *Ann Thyroid*. 2022; 7:11 (2022 Sep 30)

**Saha P**, Aller A, Deliere A, **Kuchta K**, Sullivan M, **Hulick P, Yao K**, and **DePersia A**. Application of 21-gene Breast Recurrence Score® assay to evaluate prognosis and benefit of adjuvant chemotherapy in BRCA1 and BRCA2 pathogenic variant carriers with early-stage, estrogen-receptor-positive breast cancer. Poster accepted at San Antonio Breast Cancer Symposium (SABCS). December 2022. San Antonio, Texas.

**Saha P**, Uy A, Thakkar P, **Kuchta K, Yao K**. Trends in clinical treatment of early-stage ER+PR- breast cancer in the National Cancer Database. Poster accepted at San Antonio Breast Cancer Symposium (SABCS). December 2022. San Antonio, Texas.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S ... KEYNOTE-522 Investigators (**Saha P**). Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med*. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. PMID: 35139274

Sehnm L, Noureldine S, Avci S, Isiktas G, Elshamy M, Saito Y, Abdelhamid Ahmed AH, Tierney HT, Trinh LN, **Silver Karcioglu A**, Cheung AY, Otremba M, Krishnamurthy V, Heiden K, Jin J, Shin J, Siperstein A, Zafereo M, Tufano RP, Randolph GW, Kebebew E, Milas M, Duh QY, Berber E. A Multicenter Evaluation of Near-Infrared Autofluorescence Imaging of Parathyroid Glands in Thyroid and Parathyroid Surgery. Accepted for publication in *Surgery*. 2022

Shah PH, Karagianis AG, Lester MS, **Paintal AS**, McComb EN. Calcified lymph nodes in the setting of head and neck squamous cell carcinoma: A predictor of HPV positivity? *Clin Imaging*. 2022 Jan; 81:136-142. doi: 10.1016/j.clinimag.2021.09.013. Epub 2021 Oct 5. PMID: 34710803

**Silver Karcioglu A**, Iwata AJ, Pusztaszeri M, Abdelhamid Ahmed AH, Randolph GW. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines. *Cancer Cytopathol*. 2022 Mar; 130(3):174-180. doi: 10.1002/cncy.22519. Epub 2021 Oct 7. PMID: 34618407

**Silver Karcioglu A**, Russell MD, Abdelhamid Ahmed AH, Randolph GW. Electrophysiologic RLN and Vagal Monitoring During Thyroid and Parathyroid Surgery. To be published in: *Atlas of Intraoperative Cranial Nerve Monitoring in Thyroid and Head and Neck Surgery*. Shifrin A, Deutsch AD, Randolph GW (eds). Springer, 2022

**Sisco M**, Kuchta K, Alva D, Seth A. Oral antibiotics do not prevent infection or implant loss after immediate prosthetic breast reconstruction: Evidence from 683 consecutive reconstructions without prophylaxis. *Plastic and Reconstructive Surgery*. In press.

**Somasegar S**, Hoppenot C, **Kuchta K, Sereika A, Khandekar J, Rodriguez G, Moore E, Hurteau J, Jenkins Vogel T**. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. *Gynecol Oncol*. 2021 Nov;163(2):220-228. doi: 10.1016/j.ygyno.2021.08.027. Epub 2021 Sep 9. PMID: 34511240



**Sullivan K, Kaminer LS, Grinblatt DL, Campbell NP, Nocon CC, Harper AJ, Kang JH, Sarav M, Curtis BR, Brockstein BE.** Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. *JCO Oncol Pract.* 2021 Mar;17(3):153-155. doi: 10.1200/JCO.2020.00734. Epub 2020 Dec 3. PMID: 33270522

**Tafur AJ, Moore ED.** Direct Oral Anti-Coagulants Continue to Bud into Gynecological Cancer-Thrombosis Prevention. *Clin Appl Thromb Hemost.* 2022 Jan-Dec; 28:10760296221133792. doi: 10.1177/10760296221133792. PMID: 36262075

Velu PD, Cushman-Vokoun A, Ewalt MD, Feilotter H, Gastier-Foster JM, Goswami R, Laudadio J, Olsen RJ, Johnson RL, Schlinsog A, Douglas A, Sandersfeld T, **Kaul KL.** Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists. *J Mol Diag.* 2022, in press

Vining CC, **Kuchta K**, Al Abbas Al, Hsu PJ, **Paterakos P**, Schuitevoerder D, Sood D, Roggin KK, **Talamonti MS, Hogg ME.** Bile leak incidence, risk factors and associated outcomes in patients undergoing hepatectomy: a contemporary NSQIP propensity matched analysis. *Surg Endosc.* 2022 Aug;36(8):5710-5723. doi: 10.1007/s00464-021-08938-5. Epub 2022 Apr 25. PMID: 35467144

Wu CW, Chiang FY, **Karcioglu AS**, Iwata A, Ahmed AH, Randolph GW. Rationale and Indications for Vagus/Recurrent Laryngeal Nerve Monitoring. Chapter 6 in Scharpf J and Randolph GW (eds) *Intraoperative Cranial Nerve Monitoring in Otolaryngology-Head and Neck Surgery.* Switzerland: Springer Nature, 2021; p 57-71

Wu CW, Huang TY, Randolph GW, Barczyński M, Schneider R, Chiang FY, **Silver Karcioglu A**, Wojtczak B, Frattini F, Gualniera P, Sun H, Weber F, Angelos P, Dralle H, Dionigi G. Informed Consent for Intraoperative Neural Monitoring in Thyroid and Parathyroid Surgery—Consensus Statement of the International Neural Monitoring Study Group. *Front Endocrinol (Lausanne).* 2021 Dec 7; 12:795281. doi: 10.3389/fendo.2021.795281. PMID: 34950109; PMCID: PMC8689131

Wu CW, Randolph GW, Barczyński M, Schneider R, Chiang FY, Huang TY, **Karcioglu AS**, Konturek A, Frattini F, Weber F, Liu CH, Dralle H, Dionigi G. Training Courses in Laryngeal Nerve Monitoring in Thyroid and Parathyroid Surgery—The INMSG Consensus Statement. *Front Endocrinol (Lausanne).* 2021 Jun 18; 12:705346. doi: 10.3389/fendo.2021.705346. PMID: 34220726; PMCID: PMC8253252

Xu W, Shin S, Vickman R, Filimon B, Yang Y, Hu Z, **Mangold K**, Sullivan M, **Kaul K**, **Saha P**, **Khandekar J**, Prabhkar B, Schrieber H, **Hayward S**, **Brockstein B**, and **Seth P.** The safety and efficacy of the systemic delivery of a new liver-detargeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Abstract submitted to 25th Annual Meeting of American Society of Gene & Cell Therapy (ASGCT), pending.

**Yao KA**, Attai D, Bleicher R, **Kuchta K**, Moran M, Boughy J, Wilke LG, Dietz JR, Stevens R, **Pesce C**, **Kopkash K**, Kurtzman S, Sarantou T, Victorson D. Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study). *Breast Cancer Res Treat.* 2021 Apr;186(3):625-635. doi: 10.1007/s10549-021-06101-1. Epub 2021 Jan 31. PMID: 33517522

**Zijlstra MK, Fidel Nague K, Louie P, Imas P, Sonnenberg A, Fimmel CJ.** Successful hepatitis C birth cohort screening and linkage to care in a US community health system. *J Public Health Manag Pract.* 2022 Nov-Dec;28(6): E825-E830. doi: 10.1097/PHH.0000000000001590. Epub 2022 Aug 27. PMID: 36194824

**Zijlstra MK, Silvers RI, Fimmel CJ, Krantz SB.** Esophageal perforation due to a calcium supplement tablet. *Case Rep Gastroenterol.* 2022 Jun 30;16(2):435-440. doi: 10.1159/000523952. eCollection 2022 May-Aug

Zwart MJW, Jones LR, Fuente I, Balduzzi A, Takagi K, Novak S, ... **Hogg ME**, et al. Performance with robotic surgery versus 3D- and 2D-laparoscopy during pancreatic and biliary anastomoses in a biotissue model: pooled analysis of two randomized trials. *Surg Endosc.* 2022 Jun;36(6):4518-4528. doi: 10.1007/s00464-021-08805-3. Epub 2021 Nov 19. PMID: 34799744

Zwart MJW, Jones LR, **Hogg ME**, Tol JAMG, Abu Hilal M, Daams F, Festen S, Busch OR, Besselink MG; HPB-Amsterdam. Robotic Pancreatoduodenectomy for Pancreatic Head Cancer: a Case Report of a Standardized Technique. *J Vis Exp.* 2022 Jun 24;(184). doi: 10.3791/62863. PMID: 35815992

# 2022 Academic Leadership Roles and Awards

Kellogg Cancer Center physicians are active in a broad range of regional and national organizations.

## Sameer Alvi, MD

- American Head & Neck Society—Member, Young Members Service
- American Head & Neck Society—Member, Website and Social Media Service
- Peer Reviewer, *Annals of Otolaryngology, Rhinology and Laryngology*

## Bruce Brockstein, MD

- Member, Head and Neck Committee, Eastern Cooperative Oncology Group, 2000–present

### Editorial:

- *UpToDate* (Online Textbook), Chapter Editor, *Head and Neck Cancer*, 2000–present

### Awards:

- *Chicago Magazine* Top Doctors 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2019, 2020, 2021
- *Chicago Magazine* Top Cancer Doctors 2017, 2019, 2020, 2021

## Nicholas Campbell, MD

### Editorial:

- Reviewer: *Lung Cancer, Clinical Case Reports*

## Claus Fimmel, MD, CPE

- Advisory Board, American Liver Foundation, Chicago Chapter, 2008–present

### Editorial:

- Reviewer: *Hepatology, American Journal of Gastroenterology, American Journal of Physiology, Journal of Hepatology, Journal of Laboratory and Clinical Investigation, Laboratory Investigation, American Journal of Pathology, Oncogene, Gastroenterology, Clinical Gastroenterology and Hepatology, Journal of Cellular Biochemistry, Journal of Proteome Research, Proceedings of the National Academy of Sciences, PLOS Medicine, ACG Case Reports Journal, World Journal of Hepatology*

## David Grinblatt, MD

- Community Oncology Committee, ALLIANCE for Clinical Trials in Oncology, 2010–present

### Editorial:

- Ad Hoc Reviewer, *Annals in Oncology*, 1996–present

## Brian Helfand, MD, PhD

- Guideline Review Committee for American Urologic Association Prostate Cancer Early Detection
- Guidelines Committee Member: American Urologic Association Overactive Bladder
- American Urologic Association North Central Research Committee
- Established race-specific genetic testing for prostate cancer in collaboration with GoPath Laboratories
- Principal Investigator: Blue Earth Diagnostics Study on PSMA Imaging Techniques
- Principal Investigator: NanoKnife IRE PRESERVE trial (focal therapy for prostate cancer)
- Grand Rounds: Changes in Imaging Techniques for Prostate Cancer Staging and Recurrence: UCSD, Invited Speaker
- Current Updates in Prostate Cancer; UsToo Prostate Cancer Support Group
- Grand Rounds in Urology Series: Prostate Cancer Imaging—A Patient Discussion
- Grand Rounds in Urology: Invited Speaker for Future of Genomic Testing in Urology

## Thomas Hensing, MD

- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005–present
- ALLIANCE for Clinical Trials in Oncology, Respiratory Committee Member, 2010–present
- CoC/NCDB Lung Quality Measures Group, 2011–Present
- Respiratory Health Association, Invited Member, Scientific Advisory Committee, 2019–Present

## Melissa Hogg, MD

- Hepatobiliary Disease Site Work Group Chair—SSO (Society of Surgical Oncology)
- Education Council Chair—SSO (Society of Surgical Oncology)
- HPB Task Force Co-Chair—SAGES (Society of Gastrointestinal and Endoscopic Surgery Association)
- Executive Board Advocacy Liaison—AHPBA (American Hepato-Pancreato-Biliary Association)

### Awards:

- University of Chicago—Teaching Award
- SAGES—Early Career Research Award

### Editorial Boards:

- *ASO (Annals of Surgical Oncology)* Editorial Board (Pancreas)
- Associate Editor, *Journal of Surgical Oncology*, Surgical Technique Division

## Peter J. Hulick, MD, MMSc, FACMG

- American College of Medical Genetics and Genomics representative on the CancerLinQ Oncology Leadership Council for ASCO
- Epic Genetics and Genomics Steering Board Member
- Member—Personalized Medicine Coalition Public Policy Committee
- Member—Personalized Medicine Coalition Science Policy Committee
- Director on the American Board of Medical Genetics and Genomics

### Awards:

- Newly appointed as the Janardan D. Khandekar, MD, Chair of Personalized Medicine, NorthShore University HealthSystem

## Amanda Silver Karcioglu, MD

- Completed Advanced Head and Neck Endocrine Surgery Fellowship at Harvard University—Massachusetts Eye and Ear

### National Committees:

- Patient Care and Education Committee of the American Head and Neck Society—Endocrine Surgery Section

### Invited Lecturer:

- Technology in Endocrine Surgery Course—Massachusetts Eye and Ear—Harvard University, November 4–5, 2022:
- Intraoperative Nerve Monitoring of the External Branch of the Superior Laryngeal Nerve
- Parathyroid Autofluorescence Literature Overview and Equipment: Probe and Camera
- Parathyroid Autofluorescence American Head and Neck Society White Paper and Videos
- Radiofrequency Billing

### National Presentations:

- Updates on the Surgical Variability of the Recurrent Laryngeal Nerve and Risk of Injury: A Panel Review and Presentations of Cases. (Presented on Loss of Intraoperative Nerve Monitoring Signal) AAO-HNSF 2022 Annual Meeting and OTO Experience, Philadelphia, PA, September 13, 2022.
- Parathyroid Gland Identification: More Than Meets the Eye (Presented Clinical Application of Near Infrared Autofluorescence) (NIRAF) Technology. AAO-HNSF 2022 Annual Meeting and OTO Experience, Philadelphia, PA, September 11, 2022.
- Ultrasound Nodule Risk Stratification and Artificial Intelligence. (Moderator) 7th Ankara Multidisciplinary Thyroid Cancer Symposium: International Joint Virtual Meeting. June 4, 2022.
- Which Autofluorescence System: Camera vs. Probe. Combined Otolaryngology Spring Meetings (COSM) Dallas, TX. April 28, 2022.
- Parathyroid Gland Autofluorescence: How can it help us? 13th Congress of the Istanbul Society of Otolaryngology. February 25, 2022.

## Karen Kaul, MD

- Trustee, American Board of Pathology
- Chair, Test Development and Advisory Committee for Molecular Genetics, Maintenance of Certification Committee
- Chair, Board of Directors, NorthShore Medical Group FPA, 2020–2023 (Vice-Chair 2017–2020)

### Editorial:

- Deputy Editor, *Academic Pathology*

### Invited Talks:

- A Primer in Precision Pathology: Genomics, AI and Immuno-Oncology. (Long Course), Speaker and Moderator, USCAP Annual Meeting, Los Angeles, CA, March 2022.
- Use of New Pathology Consultation Codes, Association of Pathology Chairs Annual Meeting, Chicago, IL, July 2022.
- Featured Speaker, Association of Pathology Informatics Mentoring Mondays, September 12, 2022.
- Realizing the Potential of Genomics across the Continuum of Precision Health Care. National Academy of Science, Engineering and Medicine, Roundtable on Genomics and Precision Health, Speaker and Panelist.

## Janardan D. Khandekar, MD

### Editorial:

- Associate Editor, *Journal of Surgical Oncology*
- Reviewer, *PLOS Medicine* and *Journal of Clinical Oncology*

### Grants:

- Anonymous FDN to Sequential Study Immune Response to Covid Vaccination in Cancer Patients.

### Honors:

- NorthShore has established The Janardan D. Khandekar, MD, Endowed Chair in Personalized Medicine in honor of Dr. Khandekar. The chair recognizes the extraordinary 46-year legacy of Dr. Khandekar who, as the founder of the Division of Medical Oncology and Director of the NorthShore Kellogg Cancer Center, led the way to creating today's program in genomics.

## Katherine Kopkash, MD

- Program Chair, Chicago Surgical Society
- Oncoplastics Committee, American Society of Breast Surgeons
- Principal Investigator for the FDA reviewed national trial "A Prospective, Multicenter Investigation of the da Vinci® Xi™ Surgical System in Nipple Sparing Mastectomy (NSM) Procedures"

## Seth Krantz, MD

### National Committee:

- Society of Thoracic Surgeons Health Policy and Advocacy Task Force

### Awards:

- Presidential Abstract Recognition Award, American Association for Thoracic Surgery 2022 Annual Meeting

### Editorial:

- Editorial Board: *Current Challenges in Thoracic Surgery*, 2019-present
- Reviewer: *Chest, Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, Annals of Surgical Oncology*

## Robert Marsh, MD

- Eastern Cooperative Oncology Group, GI Committee

### Editorial:

- Reviewer: *American Journal of Clinical Oncology, British Medical Journal, Cancer, Cancer Management and Research, Cell, European Journal of Surgical Oncology, Journal of Cancer Research and Clinical Oncology, Journal of Surgical Oncology, Journal of the Pancreas, The Lancet Oncology, Public Library of Science, Rogers Medical Intelligence Solutions CME Programs, Southern Medical Journal, Therapeutic Advances in Gastroenterology*

## Leslie Mendoza Temple, MD

- Co-Chair of the Oversight Committee for the International Research Congress for Integrative Medicine and Health, to be held in Cleveland, OH in April 2024.
- Co-investigator for an international Delphi study on Competency-Based Medical Education (CBME) for healthcare professionals on the subject of cannabis education for trainees with Mikhail Kogan, MD (George Washington University), Richard Israelowitz, PhD, and Yuval Zolotov, PhD (both from Ben-Gurion University of the Negev in Israel).
- Owen L. Coon Foundation Chair of Integrative Medicine awardee 2021.

*continued >*



**Catherine E. Pesce, MD**

- Breast Program Directors Subcommittee, Society of Surgical Oncology
- Institute for Healthcare Improvement Quality and Patient Safety Certificate Program, 2021–2022, completion March 2022.

*Awards:*

- Breast and Ovarian Research Program: The Auxiliary of NorthShore University HealthSystem Pilot Award. Principal Investigator: Pesce C. Title: "Universal Genetic Testing for All Newly Diagnosed Breast Cancer Patients." Project period: 6/12/20–6/12/2022.

*Presentations:*

- American Society of Breast Surgeons Annual Meeting. Invited Speaker. "ERAS Protocols in Breast Surgery." Las Vegas, NV. April 2022.
- Sharsheret National Webinar, Invited Speaker. "COVID-19 and Cancer: Two Years into This Pandemic, What We Know Today and What You Need to Know to Protect Your Health."

**Joseph Raviv, MD**

- Chicago Laryngological & Otological Society—Immediate Past President
- American Rhinologic Society (ARS)—Rhinology Training Council, Co-Director of the Annual ARS Advanced Sinus and Skull Base Course

**Gustavo Rodriguez, MD**

- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997–present
- Advisory Board, Gilda's Club, Chicago, 2004–present
- Peer Reviewer: *Gynecologic Oncology, Current Cancer Drug Targets, American Journal of Obstetrics and Gynecology*

**Carol Rosenberg, MD**

- Mentor, Scholars in Oncology-Associated Research Program at the University of Chicago Pritzker School of Medicine covering multidisciplinary and inter-professional aspects of oncology (cancer) research and clinical care. NIH/NCI grant 1R25CA240134-01
- Key Informant, Johns Hopkins University Evidence-Based Practice Center and the Agency for Healthcare Research and Quality Topic Refinement and Realist Reviewer on "Models of Pediatric-Adolescent-Adult Cancer Survivorship Care that Include Primary Care"
- Research Investigator/Topic Reviewer, Women's Health Initiative Study, National Institutes of Health

*Editorial:*

- Reviewer, *ASCO Journal of Clinical Oncology (JCO) Oncology Practice*

*Invited Presentations National:*

- American College of Surgeons Quality and Safety Conference, July 2021 virtual: Creating a Culture of Change in Survivorship. Presentation and Panelist: Title: Building an Ecosystem of Survivorship Care: NorthShore's Myra Rubenstein Weis (MRW) Living in the Future (MRW LIFE) Cancer Survivorship Program

*Awards:*

- MRW LIFE Program Grant Award Recipient to the MRW LIFE Cancer Survivorship Program: Myra Rubenstein Weis Health Resource Center, NorthShore University HealthSystem May 2022

**Daniel Shevrin, MD**

- Community Co-Chair, ECOG-ACRIN Genitourinary Committee, 2005–present
- Medical Director, NorthShore Chapter of Us TOO Prostate Cancer Support Group, 2002–present
- Director, Advocacy Core Prostate SPORE, Northwestern University, 2003–present
- Board Member, Cancer Wellness Center, Northbrook, IL, 2010–present

**Mark Sisco, MD, FACS**

- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015–present

*Editorial:*

- Editorial Board Member and Peer Reviewer, *Journal of Surgical Oncology*, 2014–present
- Peer Reviewer, *Journal of Surgical Research, Plastic and Reconstructive Surgery*
- American College of Surgeons Clinical Congress. Video Presentation. "Wise Pattern Skin-Sparing Mastectomy With Pre-Pectoral Tissue Expander Reconstruction." San Diego, CA. October 2022.

**Mark Talamonti, MD**

- PanCAN, Pancreatic Cancer Action Network, Ex Officio Member, Medical Advisory Committee
- American College of Surgeons Committee on Patient Safety and Improved Quality, High Risk GI Committee
- Americas Hepato-Pancreato-Biliary Association, Finance Committee, 2019–2021; AHPBA Member at Large, Executive Council

*Editorial:*

- Editorial Board: *Annals of Surgical Oncology, Journal of Surgical Oncology*, Section Editor: *Hepatobiliary and Pancreas*
- Invited Reviewer: *American Journal of Surgery, Annals of Surgery, Archives of Surgery, Cancer, Journal of the American College of Surgeons, Journal of Clinical Oncology, Oncology, Surgery, World Journal of Surgery*

**Lauren Wiebe, MD**

- Palliative Care Research Cooperative Group, NorthShore Site Organizational Lead, 2017–2021
- Palliative Care Research Cooperative Group, Junior Investigator, 2014–2021
- Invited Guest Speaker, Cancer Wellness Center, "The Role of Palliative Care in Cancer," December 2, 2021

*Teaching Activities:*

- Coleman National Training Program for APNs, University of Chicago, "Oncology for Palliative Care Providers," 2018–2022

*Editorial:*

- Invited Peer-Reviewer: *Journal of Palliative Medicine*, 2021

*Awards:*

- Coleman Foundation Grant: "4R Patient Care Sequences for Cancer and Supportive Care." Site Project Director for NorthShore University HealthSystem, 2019–2021
- PanCAN Patient Champion MD Award (National Award), 2021

**David J. Winchester, MD**

- Director, Rice Foundation, 1998–present
- American Joint Committee on Cancer (AJCC), 2004–present; AJCC Education and Promotions Committee, 2007–present; AJCC Finance Committee, 2008–present; Vice Chairman, 2011–present; AJCC Executive Committee, 2011–present
  - Member, Alliance ACS Clinical Research Program, 2012–present

*Editorial:*

- Member of Editorial Board, *American Journal of Clinical Oncology*, 2006–present; Associate Editor, 2009–present
- Member of Editorial Advisory Board, *American Family Physician*, 2012–present
- Member of Editorial Board, *Journal of Surgical Oncology*, 2015–present
- Ad Hoc Reviewer: *Annals of Surgical Oncology, British Journal of Cancer, Cancer, Canadian Medical Association Journal, Clinical Breast Cancer, Cancer Control: Journal of the Moffitt Cancer Center, Journal of Clinical Oncology, The Lancet Oncology, World Journal of Surgical Oncology*

*Awards:*

- Castle Connolly America's Top Doctors for Cancer (digital guide): 2016, 2017, 2018, 2019, 2020, 2021
- *Chicago Magazine*: Top Doctors: 2014, 2016, 2018, 2019, 2020, 2021

**Katharine Yao, MD**

- Member, ASCO-SSO Germline Mutation Testing in Breast Cancer Guideline Panel
- American Board of Surgery Certifying Exam Committee, Breast Section
- Practice Advocacy Committee, American Society of Breast Surgeons
- American College of Radiology, Supplemental Screening for Breast Density, Appropriateness Criteria Breast Imaging Committee
- Prevention Committee of the Alliance, Women's Cancer Working Group Chair
- The COVID-19 Pandemic Breast Cancer Consortium
- President, Chicago Surgical Society
- Chair, National Accreditation Program for Breast Centers
- Member, Quality Integration Committee, Commission on Cancer
- Member, Commission on Cancer Executive Committee
- Co-Moderator, Practical Guide to Management of Benign Breast Disease, American College of Surgeons Clinical Congress, San Diego, CA, October 2022

*Editorial:*

- Editorial Board: *Journal of Surgical Oncology, Annals of Surgical Oncology, Annals of Breast Surgery*

*Grants:*

- Mindfulness intervention and response to stress and quality of life in patients diagnosed with breast cancer. John Wayne Cancer Foundation Grant Award Recipient, Principal Investigator: Yao K
- Developing Digital Pathology for Breast Cancer Recurrence, Department of Defense Grant, Principal Investigator: Huo D (UofC) Site Principal Investigator: Yao K



# 2022 Physician Directory



**Matthew Adess, MD**  
*Medical Director, Highland Park Kellogg Cancer Center*  
 Expertise: GI Oncology; Benign and Malignant Hematology  
 Locations: GBK, HPK



**Jaime Alexander, MD**  
 Expertise: General Dermatology  
 Locations: GB, SK



**Marc Alonzo, MD**  
 Expertise: Interventional Radiology  
 Locations: EH, GB, HP, SK



**Sameer Alvi, MD**  
 Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery  
 Locations: NMB, SW



**Saad Arain, MD**  
 Expertise: Benign and Malignant Hematology  
 Locations: GBK, HPK



**Hassan Arshad, MD**  
 Expertise: Head and Neck Cancer; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery  
 Locations: EVK, NMB, SW



**Julian Bailes, MD**  
*Chair, Department of Neurosurgery Co-Director, NorthShore Neurological Institute*  
 Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery  
 Locations: EV, HPH, SW



**William Bloomer, MD**  
*Chair, Department of Radiation Oncology*  
 Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer  
 Locations: EH, HPH



**George Corneliu Bobustuc, MD**  
 Expertise: Neuro-Oncology  
 Locations: EVK, GBK, NCH



**Bruce Brockstein, MD**  
*Division Chief, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology*  
 Expertise: Head and Neck Cancers; Melanoma; Sarcoma  
 Locations: EVK, HPK



**Elizabeth Burke, MD**  
 Expertise: Oncologic Reconstruction Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery  
 Locations: NMB, SW



**Nicholas Campbell, MD**  
 Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers  
 Locations: EVK, HPK, SW



**Carolina Soto Chervin, MD**  
 Expertise: Lung Cancer; GI Oncology  
 Locations: EVK, HPK



**Shakeel Chowdhry, MD**  
 Expertise: Surgery for Aneurysms; Endovascular Treatment for Aneurysms; Arteriovenous Malformations (AVMs); Interventional Stroke Therapy; Brain Tumors; Pituitary Tumors; Spinal Tumors  
 Locations: EV, GB, NCH



**John Cieslak, MD**  
 Expertise: Interventional Radiology  
 Locations: EH, GB, HP, SK



**Jeffrey Ciley, MD**  
*Medical Director, Swedish Hospital Cancer Center, President of Medical Staff, Swedish Covenant*  
 Expertise: Benign and Malignant Hematology; Medical Oncology  
 Location: SW



**Peter Colegrove, MD**  
 Expertise: Sexual Dysfunction; Incontinence; Prostate Health; Kidney Stones; Vasectomy  
 Locations: EV, GB



**Allison DePersia, MD**  
 Expertise: Hematology Oncology; High Risk Breast Cancer  
 Location: EV



**Nisha Desai, MD**  
 Expertise: Adult and Pediatric Dermatology; General Dermatology; Laser and Surgical Treatment of Birthmarks; Hemangioma  
 Locations: MP, SK



**Michael Dombrowski, MD**  
 Expertise: Interventional Radiology  
 Locations: EH, GB, HP, SK



**Shannon Ewing, MD**  
 Expertise: General Dermatology; Laser Procedures  
 Locations: SK, WM



**Thomas Farrell, MD**  
 Expertise: Interventional Radiology  
 Locations: EH, GB, HP, SK



**Claus Fimmel, MD**  
 Expertise: Liver Diseases; Gastrointestinal Diseases; GI Endoscopy; Liver Biopsy  
 Locations: EVK, HPH, SK



**Lindsey Fraser, MD**  
 Expertise: Adult and Pediatric Dermatology; Laser and Surgical Treatment of Birthmarks; Hemangiomas  
 Location: LB



**Alla Gimelfarb, MD**  
*Medical Director, Kellogg Cancer Center Immediate Care*  
 Expertise: Benign and Malignant Hematology  
 Location: GBK



**David Grinblatt, MD**  
 Expertise: Benign and Malignant Hematology  
 Locations: EVK, GBK



**Sebouh Gueyikian, MD**  
*Section Head, Interventional Radiology*  
 Expertise: Interventional Radiology  
 Locations: EH, GB, HP, SK





**Britt Hanson, DO**  
Expertise: Melanoma, Genitourinary Cancer, Benign and Malignant Hematology  
Locations: GR, HPK



**Lynne Kaminer, MD**  
*Section Head, Hematology*  
Expertise: Benign and Malignant Hematology  
Locations: EVK, GBK



**Daniel Laich, MD**  
Expertise: Spine Tumors  
Location: SW



**Gregg Menaker, MD**  
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery  
Location: SK



**Anita Vasan Pattani, MD**  
Expertise: Internal Medicine; Hospice and Palliative Medicine  
Locations: EV, GB, HP



**Erwin Robin, MD**  
Expertise: Benign and Malignant Hematology  
Locations: GBK, HPK



**Herbert Mason Hedberg, MD**  
Expertise: Gastrointestinal and General Surgery  
Locations: EV, HP



**Amanda Silver Karcioglu, MD**  
Expertise: Head and Neck Surgery; Thyroid/Parathyroid Surgery  
Locations: EVK, LB, SK



**Elyse Lambiasi, MD**  
Expertise: Benign and Malignant Hematology; Medical Oncology  
Location: SW



**Douglas Merkel, MD**  
Expertise: Breast Cancer  
Locations: EVK, GBK, HPK



**Catherine Pesce, MD**  
*Division Chief, Surgical Oncology*  
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery  
Locations: EV, HP



**Jason Robin, MD**  
Expertise: Cardio-Oncology  
Location: GB



**Brian Helfand, MD, PhD**  
*Division Chief, Urology*  
Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery  
Location: GB



**Eileen Kelly, MD**  
Expertise: Cardio-Oncology; Clinical Cardiology  
Location: GB



**Teresa Murray Law, MD**  
Expertise: Breast Cancer  
Locations: EVK, HPK



**Cecylia K. Mizera, MD**  
Expertise: Breast Surgery; Minimally Invasive Surgery; Hernia Surgery; Gallbladder Surgery; Gastrointestinal and Colon Surgery; Robotic Assisted Surgery  
Location: SW



**Nicklas Pfnzelter, MD**  
Expertise: Genitourinary Cancer, Lung Cancer, Melanoma  
Locations: EVK, GBK, HPK



**Gustavo Rodriguez, MD**  
*Division Chief, Gynecologic Oncology*  
Expertise: Gynecologic Oncology  
Location: EVK



**Thomas Hensing, MD, MS**  
*Co-Director of the Thoracic Oncology Program, Associate Chief Quality Officer for Ambulatory Care*  
Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers  
Locations: EVK, GBK



**James Kearns, MD**  
Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery  
Locations: EV, GB



**Ross Levy, MD**  
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery  
Location: SK



**Tricia Moo-Young, MD**  
Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Cancer and Disease Management  
Locations: HPH, SK




**Elizabeth Poli, MD**  
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery  
Locations: HPH, VH



**Carol Rosenberg, MD**  
*Director, Preventive Health Initiatives; Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program*  
Expertise: Cancer Survivorship  
Location: HPH



**Melissa Hogg, MD, MS**  
*Director, Liver and Pancreas Surgery*  
Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Primary and Metabolic Liver Tumors; Neuroendocrine Tumors; Cancers of the Stomach and Duodenum; Benign Hepatobiliary  
Locations: EVK, SW




**Janardan Khandekar, MD**  
*Director, Center for Molecular Medicine*  
Expertise: Endocrine; Breast Cancer  
Location: EV



**Melissa Hachen Lippitt, MD, MPH**  
Expertise: Gynecologic Oncology  
Locations: EVK, GBK



**Elena Moore, MD**  
Expertise: Gynecologic Oncology  
Locations: EVK, HPK



**Ariel Polish, MD**  
Expertise: GI Oncology; Benign and Malignant Hematology; Genitourinary Cancer; Lung Cancer  
Locations: EVK, GBK, GR



**Poornima Saha, MD**  
Expertise: Breast Cancer  
Locations: EVK, GBK



**Peter Hulick, MD, MMSc**  
*Division Chief, Medical Genetics Director, Center for Personalized Medicine*  
Expertise: Cardiovascular and Cancer Genetics; Pharmacogenomics; Personalized Medicine  
Location: EV



**Carolyn Kirschner, MD**  
Expertise: Gynecologic Oncology; Cancer Survivorship  
Locations: EVK, GBK



**Luzheng Liu, MD**  
Expertise: General Dermatology; Skin Cancers  
Location: LB



**Joseph Muldoon, MD**  
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; General Surgery  
Locations: EV, GB



**Amit Pursnani, MD**  
Expertise: Cardio-Oncology  
Location: SK



**Akhil Seth, MD**  
Expertise: Breast Reconstruction; Aesthetic Breast and Body Surgery; Oncologic Reconstruction  
Location: NMB



**Javed Imam, MD**  
Expertise: Benign and Malignant Hematology, Medical Oncology  
Location: SW



**Madhuri Konanahalli, MD**  
Expertise: Skin Cancer; General Dermatology  
Locations: EV, WM




**Janette Maldonado, MD**  
Expertise: Minimally Invasive Surgery; Gallbladder Surgery; Hernia Surgery; Partial Colectomy  
Location: SW



**Ranjeev Nanda, MD**  
Expertise: Stereotactic Radiosurgery; Brain Tumors; Head and Neck Cancers; Prostate Cancer  
Locations: EH, GBH



**Vathsala Raghavan, MD**  
Expertise: Thyroid Cancer; Breast Cancer; Gynecologic Oncology; Head and Neck Cancers  
Locations: GBH, HPH



**Arif Shaikh, MD**  
Expertise: Stereotactic Radiosurgery; Head and Neck Cancers; Lung Cancer; Gynecologic and Breast Tumors; Prostate Cancer  
Locations: EH, GBH



**Mary Tilley Jenkins Vogel, MD**  
Expertise: Gynecologic Oncology  
Locations: EVK, GBK, SW



**Katherine Kopkash, MD**  
*Director of Oncoplastic Breast Surgery*  
Expertise: Breast Cancer; Oncoplastic Breast Surgery; Breast Health; Breast Disease and Surgery  
Locations: EV, GB




**Robert Marsh, MD**  
*Section Head, GI Oncology*  
Expertise: GI Oncology  
Locations: EVK, GBK



**Kristian Novakovic, MD**  
Expertise: Bladder Cancer; Kidney Cancer; Prostate Cancer; Minimally Invasive Techniques: Laparoscopy and daVinci Robot  
Locations: EV, GB



**Joseph Raviv, MD**  
*Division Chief, Otolaryngology*  
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery  
Locations: NMB, SK, SKM



**Daniel Shevrin, MD**  
*Medical Director, Glenbrook Kellogg Cancer Center*  
Expertise: Prostate Cancer; Genitourinary Cancer  
Locations: EVK, GBK



**Andrew Johnson, MD**  
Expertise: Neurological Surgery, Neurosurgery, Cervical Spine Surgery, Minimally Invasive Spine Surgery; Complex Spine Surgery, Brain and Spine Tumors  
Location: SW



**Seth Krantz, MD**  
Expertise: Lung Cancer; Esophageal Cancer; Benign Esophageal Disease, Diseases of the Chest Wall and Pleura, Minimally Invasive Thoracic Surgery, Bronchoscopy, Endobronchial Ultrasound, Esophagoscopy  
Locations: EVK, HPK



**Stephanie Mehlis, MD**  
Expertise: Blistering Diseases; Connective Tissue Diseases; Atopic Dermatitis; Hidradenitis Suppurativa; Inflammatory Skin Diseases; Psoriasis; Vitiligo; Alopecia Areata  
Location: SK




**Sangtae Park, MD, MPH**  
Expertise: Prostate Cancer; Urologic Oncology  
Locations: EV, GB



**Sidney Regalado, MD**  
Expertise: Interventional Radiology  
Locations: EH, GB, HP, SK



**Mark Sisco, MD**  
*Division Chief, Plastic Surgery*  
Expertise: Aesthetic Surgery; Breast Reconstruction; Microsurgery  
Location: NMB



**Joel Joyce, MD**  
Expertise: Pediatric Dermatology; Laser and Surgical Treatment of Birthmarks; Hemangiomas  
Locations: SK, WP



**Monika Krezalek, MD**  
Expertise: Minimally Invasive Colon and Rectal Surgery; Inflammatory Bowel Disease; Anorectal Surgery; Colonoscopy; Pelvic Floor Disorders  
Locations: EV, HPH, VH



**Andrew Melnyk, MD**  
Expertise: Medical Genetics—All Ages; Genetic Syndromes/Hereditary Disorders; Cancer Genetics  
Location: EV



**Rupa Patil, MD**  
Expertise: Cardio-Oncology  
Locations: EV, GB, MRW



**Mary Rhodes, MD**  
Expertise: Internal Medicine; Hospice and Palliative Medicine  
Locations: EV, GB, HP



**Norm Smith, MD**  
Expertise: Bladder Cancer; Testicular Cancer; Kidney Cancer; Advanced Urologic Cancers  
Locations: EV, GB





**Thomas (T.J.) Smith, MD**  
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery  
Location: SW



**Elaine Lee Wade, MD**  
Expertise: Breast Cancer  
Location: GBK



**Alan Smookler, MD**  
*Division Chief, Palliative Care*  
Expertise: Internal Medicine; Geriatrics; Hospice and Palliative Medicine  
Location: GBK



**Jason Waldinger, MD**  
*Division Chief, Dermatology*  
Expertise: General Dermatology; Laser Procedures  
Location: LB



**James Spitz, MD**  
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancers; Advanced Lower Endoscopy  
Locations: GB, HPH, VH



**Amy Wang, MD**  
Expertise: Benign and Malignant Hematology  
Location: EVK



**Katherine Wailen Su, MD**  
Expertise: Lung Cancer; Esophageal Cancer; Benign Esophageal Disease; Paraesophageal Hernias; Mediastinal Masses; Diseases of Chest Wall and Pleura; Minimally Invasive Surgery; Advanced Endoscopy/Bronchoscopy  
Locations: EVK, NCH



**Lauren Wiebe, MD**  
Expertise: Internal Medicine; Palliative Medicine; GI Oncology  
Locations: EVK, GBK



**Auddie Sweis, MD**  
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery  
Locations: LB, SKM, SW



**David J. Winchester, MD**  
*Associate Medical Director for Surgical Services, Kellogg Cancer Center*  
Expertise: Surgical Oncology with Emphasis on Breast, Endocrine, Melanoma and Sarcoma  
Locations: GB, GBM, SK



**Mark Talamonti, MD**  
*Department Chair, Surgery*  
Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Benign and Malignant Liver Tumors; Neuroendocrine Tumors; Foregut Cancers of the Esophagus; Sarcoma  
Location: EVK



**Ricky Wong, MD**  
Expertise: Deep Brain and Vagal Nerve Stimulators; Brain and Skull Base Tumors; Pituitary Tumors; Cerebral Aneurysms; Arteriovenous Malformation (AVM); Trigeminal Neuralgia  
Locations: EV, GB, NCH



**Leslie Mendoza Temple, MD**  
*Medical Director, Integrative Medicine*  
Expertise: Integrative Medicine  
Location: GP



**Katharine Yao, MD**  
*Vice Chair, Research and Development*  
*Department of Surgery*  
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery  
Locations: EV, GB



**Michael Ujiki, MD**  
*Division Chief, Gastrointestinal & General Surgery*  
Expertise: Minimally Invasive Surgery; Esophageal Surgery; Gastric Surgery; Bariatric Surgery; Flexible Endoscopy; Gallbladder Surgery  
Locations: EV, GB



**Andrew Zelby, MD**  
Expertise: Pituitary Tumors  
Location: LV

## Cancer Conferences

### Breast Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868, Mondays, 7:30 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Colorectal Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868  
2nd and 4th Fridays, 7 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Genitourinary Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868  
1st and 3rd Fridays, 7 a.m.  
NorthShore Glenbrook Hospital Videocast*

### Gynecology Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868, Thursdays, 7 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Head and Neck Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868  
1st and 3rd Thursdays, 8 a.m.*

### Hematology/Pathology Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868, Tuesdays, 8 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Hepatic Biliary Pancreatic Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868, Tuesdays, 7 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Molecular Oncology Conferences

*NorthShore Evanston Hospital  
Kellogg Room 4818, 1st Friday, 7 a.m.*

### Neuro-Oncology Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868  
2nd and 4th Wednesdays, 7:30 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Sarcoma/Melanoma Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868  
1st and 3rd Wednesdays, 8 a.m.  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

### Thoracic Cancer Conferences

*NorthShore Evanston Hospital  
Kellogg Room G868, Tuesdays, noon  
NorthShore Glenbrook and Highland Park  
Hospitals Videocast*

## Locations

### Evanston Breast Center (EVB)

2650 Ridge Avenue, Evanston, IL 60201

### Evanston Hospital (EH)

2650 Ridge Avenue, Evanston, IL 60201

### Evanston Kellogg Cancer Center (EVK)

2650 Ridge Avenue, Evanston, IL 60201

### Evanston Specialty Suites (EV)

1000 Central Street, Evanston, IL 60201

### Glenbrook Breast Center (GBB)

2050 Pfingsten Road, Suite 130  
Glenview, IL 60026

### Glenbrook Hospital (GBH)

2100 Pfingsten Road, Glenview, IL 60026

### Glenbrook John and Carol Walter Ambulatory Care Center (GB)

2180 Pfingsten Road, Glenview, IL 60026

### Glenbrook Kellogg Cancer Center (GBK)

2180 Pfingsten Road, Suite 1000  
Glenview, IL 60026

### Glenbrook Medical Building (GBM)

2050 Pfingsten Road, Suite 128  
Glenview, IL 60026

### Glenview Park Center (GP)

2400 Chestnut Avenue, Glenview, IL 60026

### Gurnee Ambulatory Care Center (GR)

7900 Rollins Road, Gurnee, IL 60031

### Highland Park Ambulatory Care Center (HPS)

757 Park Avenue West  
Highland Park, IL 60035

### Highland Park Breast Center (HPB)

777 Park Avenue West, Suite B400  
Highland Park, IL 60035

### Highland Park Hospital (HPH)

777 Park Avenue West, Room 1260  
Highland Park, IL 60035

### Highland Park Kellogg Cancer Center (HPK) – Ellen Marks Ambulatory Care Center

757 Park Avenue West, Suite 1810  
Highland Park, IL 60035

### Highland Park Medical Building (HP)

767 Park Avenue West, Suite B100  
Highland Park, IL 60035

### Lake Bluff Medical Building (LB)


71 Waukegan Road, Suite 700  
Lake Bluff, IL 60044

### Lakeview Medical Group (LV)

3122 N. Ashland Avenue  
Chicago, IL 60657

### Mount Prospect Medical Building (MP)

1329 Wolf Road, Mount Prospect, IL 60056



### Northbrook Medical Building (NMB)

501 Skokie Boulevard  
Northbrook, IL 60062

### NorthShore Medical Group (SKM) – Skokie

9933 Woods Drive, Suite 200  
Skokie, IL 60077

### Northwest Community Healthcare (NCH)

880 West Central Road, Suite 4100  
Arlington Heights, IL 60005

### Skokie Ambulatory Care Center (SK)

9650 Gross Point Road, Suite 3000  
Skokie, IL 60076

### Skokie Medical Group (SKM)

9669 Kenton Avenue, Suite 206  
Skokie, IL 60076

### Swedish Hospital (SW)

5140 N. California Avenue  
Chicago, IL 60625

### Vernon Hills Specialty Suites (VH)

225 North Milwaukee Avenue  
Vernon Hills, IL 60061

### Wilmette Medical Office (WM)

1515 Sheridan Road, Suite 31A  
Wilmette, IL 60091



**Evanston Hospital**

2650 Ridge Avenue, Evanston, Illinois 60201  
(847) 570-2000

**Glenbrook Hospital**

2100 Pfingsten Road, Glenview, Illinois 60026  
(847) 657-5800

**Highland Park Hospital**

777 Park Avenue West, Highland Park, Illinois 60035  
(847) 432-8000

**Northwest Community Healthcare/Hospital**

800 West Central Road, Arlington Heights, IL 60005  
(847) 618-1000

**Skokie Hospital**

9600 Gross Point Road, Skokie, Illinois 60076  
(847) 677-9600

**Swedish Hospital**

5140 N. California Avenue, Chicago, IL 60625  
(773) 878-8200

**Medical Group**

1301 Central Street, Evanston, Illinois 60201  
(847) 570-5235

**Foundation**

1033 University Place, Suite 450  
Evanston, Illinois 60201  
(224) 364-7200


**Research Institute**

1001 University Place, Evanston, Illinois 60201  
(224) 364-7100



1301 Central Street  
Evanston, Illinois 60201

[northshore.org](http://northshore.org)



Scan for more information

# 2022 Cancer Committee

## Chairman

**David J. Winchester, MD, FACS**

Associate Director for Surgical Specialties,  
Kellogg Cancer Center

## Cancer Liaison Physician

**Seth Krantz, MD**

Division Chief, Thoracic Oncology

## Ancillary Membership

**Jonella Black, PT, MS**

Rehabilitation Services

**Kim Cholewa, BSN**

Clinical Nurse Manager,  
5S Searle

**Anisha Patel, APN**

Clinical Coordinator,  
MRW Living in the Future  
(LIFE) Cancer Survivorship  
Program

## Physician Membership\*

**Matthew Adess, MD**

Medical Director, Highland Park  
Kellogg Cancer Center

**Catherine Pesce, MD**

Division Chief, Surgical Oncology

**Bruce Brockstein, MD**

Medical Director,  
Kellogg Cancer Center  
Head, Division of Hematology/Oncology  
Kellogg-Scanlon Chair of Oncology

**Nicklas Pfanzelter, MD**

Clinical Research Coordinator  
Quality Improvement Coordinator

**David Grinblatt, MD**

Director, Oncology Research Program

**Vathsala Raghavan, MD**

**Carol Rosenberg, MD**  
Director, Myra Rubenstein Weis  
Living in the Future (LIFE)  
Cancer Survivorship Program  
Survivorship Program Coordinator

**Monika Krezalek, MD****Elena Moore, MD****Kristian Novakovic, MD****Ajit Paintal, MD****Poornima Saha, MD**

**Georgia Spear, MD**  
Section Chief, Breast Imaging

**Lauren Wiebe, MD****Jamie Feld, RN**

Cancer Committee Nurse  
Coordinator

**Sharon Huginnie**

Senior Applications Analyst I  
Epic IP/HOV Team  
Health Information Technology

**Elizabeth Kacel PhD**

Clinical Psychologist

**Aviva Matanky, RN, OCN**

Clinical Nurse Manager,  
Evanston Kellogg Cancer Center

**Rachel Mees**

Assistant Vice President,  
Medical Group  
Kellogg Cancer Center

**Sabina Omercajic, MS, CCRP**

Outreach Coordinator

**Dipale Patel**

Senior Director, Oncology  
Pharmacy

**Shayna Purcell, MS, CGC**

Medical Genetics

**Aubree Thelen**

Cancer Control Strategic  
Partnerships Manager  
American Cancer Society

**Colette Urban**

Director, Public Relations  
Corporate Communications

**Irene Ziaya, LCSW**

Psychosocial Services  
Coordinator

**Debra Ziegler, MLIS, CTR**

Cancer Registry Quality  
Coordinator  
Cancer Conference  
Coordinator

**Lisa Zoberman, RDN, LDN**

Oncology Nutrition

\* All academic affiliations are with the University of Chicago Pritzker School of Medicine